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Abstract	  
A-­‐kinase	   anchoring	   proteins	   (AKAPs)	   control	   the	   localization	   of	   cAMP-­‐dependent	   protein	   kinase	   A	  
(PKA)	  by	  tethering	  PKA	  to	  distinct	  cellular	  compartments.	  Through	  additional	  direct	  protein-­‐protein	  
interactions	  with	  PKA	  substrates	  and	  other	  signaling	  molecules	   they	   form	  multi-­‐protein	  complexes.	  
Thereby,	  AKAPs	  regulate	  the	  access	  of	  PKA	  to	  its	  substrates	  in	  a	  temporal	  and	  spatial	  manner	  as	  well	  
as	  the	  local	  crosstalk	  of	  cAMP/PKA	  with	  other	  signaling	  pathways.	  
Due	  to	  the	   increasing	   information	  on	  their	  molecular	  functioning	  and	  three-­‐dimensional	  structures,	  
and	   their	   emerging	   roles	   in	   the	   development	   of	   diseases,	   AKAPs	  move	   into	   the	   focus	   as	   potential	  
drug	   targets.	   In	   particular,	   targeting	   AKAP-­‐dependent	   protein-­‐protein	   interactions	   for	   interference	  
with	   local	  signal	  processing	   inside	  cells	  potentially	  allows	  for	  the	  development	  of	  therapeutics	  with	  
high	  selectivity	  and	  fewer	  side	  effects.	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Introduction	  
A-­‐kinase	   anchoring	   proteins	   (AKAPs)	   are	   a	   family	   of	   more	   than	   50	   scaffolding	   proteins	   (including	  
splice	  variants)	  whose	  common	  denominator	  is	  the	  ability	  to	  directly	  bind	  cAMP-­‐dependent	  protein	  
kinase	   (protein	   kinase	   A,	   PKA),	   a	   serine/threonine	   kinase.	   In	   its	   inactive	   state	   PKA	   holoenzyme	  
consists	   of	   two	   catalytic	   (C)	   and	   two	   regulatory	   (R)	   subunits.	   Stimulation	   of	   G	   protein-­‐coupled	  
receptors	  (GPCRs)	  on	  the	  surface	  of	  cells	  and	  subsequent	  activation	  of	  the	  stimulatory	  G	  protein	  Gs	  
leads	  to	  activation	  of	  adenylyl	  cyclase	  (AC)	  to	  synthesize	  the	  second	  messenger	  cAMP.	  Upon	  binding	  
of	   two	   molecules	   of	   cAMP	   to	   each	   R	   subunit	   of	   PKA	   conformational	   changes	   occur	   and	   PKA	   is	  
activated:	  the	  C	  subunits	  are	  released	  and	  in	  this	  active	  form	  phosphorylate	  nearby	  targets	  (Fig.	  1).	  
Four	  different	  R	  subunit	  (RIα,	  RIβ,	  RIIα	  and	  RIIβ)	  and	  three	  different	  C	  subunit	  isoforms	  (Cα,	  Cβ,	  Cγ)	  
are	   expressed	   in	   mammalian	   cells,	   and	   various	   splice	   variants	   have	   been	   reported.	   The	   C	   and	   R	  
subunits	  can	  assemble	   in	  several	  combinations	  and	  give	  rise	  to	  a	  variety	  of	  PKA	  holoenzymes	  [1-­‐5].	  
AKAPs	  bind	  R	  subunits	  of	  PKA.	  Based	  on	  their	  R	  subunit	  selectivity,	  AKAPs	  are	  categorized	  as	  RI-­‐,	  RII-­‐	  
or	  dual-­‐specific	  (D-­‐)AKAPs	  if	  they	  bind	  both	  RI	  and	  RII	  [6-­‐8].	  
	  
Figure	  1:	   Compartmentalized	   cAMP	  signaling.	   Levels	  of	   the	   second	  messenger	   cAMP	   increase	   in	   response	   to	   a	  plethora	  of	   stimuli	   that	  
activate	  G	  protein-­‐coupled	  receptors	  (GPCR),	  which	  in	  turn	  stimulate	  the	  heterotrimeric	  G	  protein	  Gs	  (α,	  β	  and	  γ	  subunits)	  and	  synthesis	  of	  
cAMP	  by	  adenylyl	  cyclase	  (AC).	  cAMP	  is	  degraded	  by	  phosphodiesterases	  (PDEs).	  The	  strategic	  positioning	  of	  PDEs	  establishes	  gradients	  of	  
cAMP	  inside	  cells,	  which	  are	  sensed	  by	  cAMP	  effectors	  such	  as	  protein	  kinase	  A	  (PKA).	  The	  effectors	  are	  tethered	  to	  defined	  cellular	  sites	  
and	  transform	  local	  cAMP	  elevations	  into	  specific	  cellular	  responses	  to	  each	  of	  the	  external	  stimuli.	  This	  compartmentalization	  of	  PDEs	  and	  
cAMP	  effectors	  is	  achieved	  by	  scaffolding	  proteins	  such	  as	  A-­‐kinase	  anchoring	  proteins	  (AKAPs).	  AKAPs	  tether	  multi-­‐protein	  complexes	  to	  
defined	   cellular	   locations	   and	   spatially	   and	   temporally	   coordinate	   cellular	   signaling	   processes.	   Aberrations	   in	   compartmentalized	   cAMP	  
signaling	   are	   associated	   with	   a	   range	   of	   diseases,	   including	   cancer,	   cardiovascular,	   neurological	   and	   inflammatory	   diseases.	   Targeting	  
components	  of	   this	   system	  pharmacologically	  may	  pave	   the	  way	   to	  new	  concepts	   for	   the	   treatment	  of	  diseases	  with	  an	  unmet	  medical	  
need.	  R	  and	  C,	  regulatory	  and	  catalytic	  subunits	  of	  PKA,	  respectively.	  
A	  plethora	  of	  extracellular	  cues	  leads	  to	  activation	  of	  the	  Gs/AC/PKA	  system	  of	  which	  all	  components	  
are	  ubiquitously	  expressed.	  Through	  unique	  anchoring	  domains	  AKAPs	  tether	  PKA	  to	  defined	  cellular	  
compartments	   (e.g.	   to	   the	   cytoskeleton,	   plasma	   membrane,	   the	   Golgi,	   vesicles,	   nucleus	   or	  
mitochondria),	   and	   thereby	   regulate	   PKA	   signaling	   spatially	   and	   temporally	   (Fig.	   2)	   [7,	   9,	   10].	   The	  
interaction	  of	  AKAPs	  with	  PKA	  increases	  the	  specificity	  of	  PKA	  signaling	  and	  facilitates	  specific	  cellular	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responses	   to	   each	   of	   the	   extracellular	   cues.	   AKAPs	   are	   engaged	   in	   further	   direct	   protein-­‐protein	  
interactions.	   Interactions	   with	   PKA	   substrates	   enable	   PKA	   to	   phosphorylate	   its	   local	   protein	  
substrates	  and	  thereby	  to	  modulate	  their	  activities.	  In	  addition,	  AKAPs	  bind	  GPCRs	  [11],	  ACs	  [12,	  13],	  
exchange	   proteins	   directly	   activated	   by	   cAMP	   (Epac)	   [14],	   phosphodiesterases	   (PDEs)	   [15,	   16],	  
protein	   kinases	   (e.g.	   protein	   kinases	   C,	   D	   and	  N)	   [17],	   protein	   phosphatases	   such	   as	   PP1	   [18]	   and	  
PP2B	   (calcineurin)	   [19,	   20]	   and	   ion	   channels	   and	   pumps	   (e.g.	   L-­‐type	   Ca2+	   channels,	   Na+-­‐Ca2+	  
exchangers	  [21]).	  A	  few	  AKAPs	  additionally	  possess	  catalytic	  activity,	  e.g.	  the	  Rho	  guanine	  nucleotide	  
exchange	  factor	  (RhoGEF)	  activity	  of	  AKAP-­‐Lbc	  (Lymphoid	  blast	  crisis)	  that	  activates	  the	  small	  GTPase	  
RhoA	   [22]	   and	   the	   GTPase	   activity	   of	   Rab32	   hydrolyzing	   GTP	   [23];	   as	   activities	   of	   some	   of	   the	  
interacting	  proteins	  are	  modulated	  by	  second	  messengers	  other	  than	  cAMP,	  e.g.	  Ca2+,	  AKAPs	  are	  not	  
simple	  scaffolds	  but	  rather	  coordinate	  the	  crosstalk	  of	  cellular	  signaling	  processes.	  
	  
Figure	   2:	   Every	   organelle	   and	   subcellular	   compartment	   such	   as	   F-­‐actin	  within	   the	   cytoplasm	   possesses	   one	   or	  more	   AKAPs.	   Several	  
organelles	  and	  the	  F-­‐actin	  cytoskeleton	  are	  shown	  with	  an	  exemplary	  set	  of	  AKAPs.	  
In	   vitro,	   cell-­‐based	   and	   in	   vivo	   studies	   including	   knockdown	   approaches	   and	   gene	   targeting	   are	  
shedding	   light	   on	   physiological	   functions	   and	   the	   pathophysiology	   of	   AKAPs.	   From	   the	   variety	   of	  
studies	  it	  is	  clear	  that	  many	  cellular	  processes	  such	  as	  the	  regulation	  of	  cell	  cycle	  and	  cell	  migration	  
[24],	  cardiac	  contractility	  [21,	  25-­‐28],	  sperm	  motility	  [29-­‐31],	  insulin	  secretion	  [32]	  and	  T	  cell	  immune	  
responses	   [33]	   are	   dependent	   on	   AKAPs.	   The	   pharmacological	   interference	   with	   defined	   AKAP-­‐
dependent	  protein-­‐protein	  interactions	  has	  elucidated	  roles	  of	  specific	  interactions.	  Most	  prominent,	  
interactions	  between	  AKAPs	   and	  PKA	  have	  been	  disrupted	  with	   various	  pharmacological	   agents	   to	  
reveal,	   for	   example,	   that	   these	   interactions	   are	   crucial	   for	   arginine-­‐vasopressin	   (AVP)-­‐mediated	  
water	  reabsorption	  in	  renal	  principal	  cells	  [34]	  and	  cardiac	  myocyte	  contractility	  [27,	  35-­‐37].	  	  
The	   increasing	   insight	   into	  their	  physiological	   functioning	  and	  structures,	  and	  the	  emerging	  roles	  of	  
AKAPs	   in	   the	   development	   of	   diseases,	   move	   AKAPs	   into	   the	   focus	   as	   potential	   drug	   targets.	   In	  
particular,	   AKAP-­‐dependent	   protein-­‐protein	   interactions	   appear	   promising	   for	   pharmacological	  
interference	   with	   local	   signal	   processing	   inside	   cells	   and	   the	   development	   of	   therapeutics	   with	  
potentially	  high	  selectivity	  and	  efficacy.	  However,	  AKAPs	  are	  not	  yet	  established	  drug	  targets.	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Here,	  we	  review	  new	  insights	  into	  AKAP-­‐mediated	  signaling	  events,	  the	  relevance	  of	  AKAPs	  in	  health	  
and	   various	   diseases	   (Tab.	   1),	   structural	   aspects	   of	   AKAPs	   and	   their	   interactions,	   the	   current	  
developments	  of	  pharmacological	  agents	  targeting	  AKAPs	  and	  their	  interactions	  (Tab.	  2),	  and	  allude	  
to	  potential	  therapeutic	  options	  involving	  AKAPs.	  	  
Physiological	   relevance	   of	   AKAPs	   and	   their	   implication	   in	   disease	   -­‐	   options	   for	   pharmacological	  
interference	  with	  AKAP-­‐dependent	  protein-­‐protein	  interactions	  
AKAPs	  in	  the	  heart	  
β-­‐adrenoreceptor	   stimulation	   on	   the	   surface	   of	   cardiac	  myocytes	  mediates	   activation	   of	   PKA.	   PKA	  
phosphorylates	  several	  substrates,	  amongst	  others	  L-­‐type	  Ca2+	  channels,	  type	  2	  ryanodine	  receptors	  
(RyR2),	  phospholamban	  (PLN),	  phospholemman,	  Troponin	  I	  (TnI)	  and	  myosin-­‐binding	  protein	  (MyBP).	  
The	  net	  effect	  of	  the	  PKA	  phosphorylations	  is	  an	  increase	  in	  contractility	  (positive	  inotropic,	  positive	  
chronotropic	  and	  positive	   lusitropic	  effects).	  The	  phosphorylations	  are	   facilitated	  by	   interactions	  of	  
PKA	  with	  AKAPs	  and	  the	  tethering	  of	  the	  AKAP-­‐PKA	  complexes	  to	  PKA	  substrates.	  One	  example	  is	  the	  
complex	   comprising	   AKAP18δ,	   PKA,	   PLN	   and	   sarcoplasmic	   reticulum	   (SR)	   Ca2+	   ATPase	   2	   (SERCA2).	  
AKAP18δ	   directly	   interacts	   with	   PKA	   and	   PLN	   and	   facilitates	   β-­‐adrenoreceptor-­‐induced	   and	   PKA-­‐
catalyzed	   phosphorylation	   of	   PLN.	   Phosphorylated	   PLN	   is	   released	   from	   its	   direct	   interaction	  with	  
SERCA2,	  activating	  SERCA2.	  The	  result	  is	  an	  enhanced	  Ca2+	  re-­‐uptake	  into	  the	  SR	  and	  relaxation	  of	  the	  
myocyte	  [38].	  	  
There	   are	  more	   than	   10	   AKAPs	   expressed	   in	   cardiac	  myocytes,	   e.g.	   Yotiao	   controlling	   KCNQ1	   and	  
mAKAP	   controlling	   RyR2	   [21];	   AKAP79,	   AKAP18α	   (Fig.	   3)	   and	   Cypher	   all	   interact	   with	   L-­‐type	   Ca2+	  
channels	  [19,	  39-­‐41],	  although	  the	  functional	  implications	  of	  these	  interactions	  are	  not	  entirely	  clear	  
[42].	  For	  the	  majority	  of	  cardiac	  AKAPs	  the	  physiological	  function	  remains	  to	  be	  determined.	  
The	   heart	   responds	   to	   stress	   by	   an	   adaptive	   process	   resulting	   in	   cardiac	   hypertrophy,	   a	   condition	  
characterized	   by	   increases	   in	   cardiac	  myocyte	   size	   and	   total	   cardiac	  mass;	   is	   the	   stress	   persistent,	  
hypertrophy	   can	   progress	   towards	   heart	   failure.	   Major	   risk	   factors	   for	   the	   development	   of	  
myocardial	   hypertrophy	   and	   thus	   heart	   failure	   are	   pressure	   and	   volume	   overload	   resulting	   for	  
example	  from	  hypertension	  and	  myocardial	  infarction.	  	  
The	   protein	   expression	   level	   of	   several	   AKAPs	   is	   altered	   in	   hypertrophic	   cardiac	   myocytes.	   A	  
prototypical	  example	  of	  an	  AKAP	  involved	  in	  cardiac	  hypertrophy	  is	  AKAP-­‐Lbc	  (Fig.	  3).	  Its	  expression	  is	  
upregulated	   in	   mouse	   hearts	   upon	   cardiac	   stress,	   induced	   by	   phenylephrine	   and	   angiotensin	   II	  
infusion	   or	   thoracic	   aortic	   constriction	   (TAC)	   [26].	   Heart	   biopsies	   from	   patients	   suffering	   from	  
hypertrophic	  cardiomyopathy	  revealed	  increased	  AKAP-­‐Lbc	  transcript	  levels	  [26].	  AKAP-­‐Lbc’s	  multiple	  
interactions	  with	  PKA,	  protein	  kinases	  C,	  D,	  Nα	  and	  p38	  MAPK	  as	  well	  as	  its	  ability	  to	  act	  as	  a	  RhoGEF	  
to	  activate	  RhoA	  are	  all	  involved	  in	  the	  development	  of	  hypertrophy	  [17,	  43-­‐47].	  In	  line,	  knockdown	  
of	   AKAP-­‐Lbc	   in	   cultured	   cardiac	   myocytes	   using	   shRNA	   reduces	   α1-­‐adrenoceptor-­‐mediated	   RhoA	  
activation	   and	   hypertrophic	   responses	   [48].	   In	   cardiac	   fibroblasts,	   AKAP-­‐Lbc	   is	   involved	   in	   the	  
reprogramming	  towards	  cardiomyoblasts,	  cells	  that	  cause	  fibrosis,	  a	  maladaptation	  occurring	  during	  
the	  remodeling	  of	  the	  heart	  and	  that	   is	  associated	  with	  the	  development	  towards	  hypertrophy	  and	  
heart	   failure	   [49].	   Surprisingly,	   AKAP-­‐Lbc	   apparently	   has	   not	   only	   pro	   but	   also	   anti-­‐hypertrophic	  
functions.	   In	   a	   mouse	   model	   where	   AKAP-­‐Lbc	   is	   deficient	   for	   PKD	   binding,	   the	   animals	   become	  
sensitized	   to	   stress	   induced	   by	   angiotensin	   II	   and	   phenylephrine	   treatment	   as	  well	   as	   to	   TAC.	   The	  
mice	   display	   attenuated	   compensatory	   cardiac	   hypertrophy,	   increased	   collagen	   deposition	   and	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apoptosis,	   compared	   to	   their	  wild	   type	   littermates	   indicating	   the	   relevance	   of	   the	   AKAP-­‐Lbc-­‐PKD1	  
interaction	  to	  enhance	  cardiac	  performance	  in	  response	  to	  stress	  [47].	  A	  second	  AKAP	  whose	  role	  in	  
cardiac	  hypertrophy	  has	  been	   intensively	   studied	   is	  mAKAP.	   For	  details	   the	   reader	   is	   referred	   to	   a	  
recent	  review	  [50].	  
	  
Figure	   3:	  A	   role	   of	   AKAP-­‐Lbc	   in	   the	   development	   of	   cardiac	  myocyte	   hypertrophy.	   Stimulation	   of	   α1-­‐	   or	   β-­‐adrenoreceptors	   leads	   to	  
activation	  of	  G	  protein-­‐mediated	  signaling	  pathways	  in	  cardiac	  myocytes	  involving	  AKAP-­‐Lbc.	  PKA	  anchors	  R	  subunits	  of	  PKA	  via	  the	  AKB	  
while	  the	  DH/PH	  domain	  of	  AKAP-­‐Lbc	  binds	  and	  activates	  the	  small	  GTPase	  RhoA,	  followed	  e.g.	  by	  Rho-­‐mediated	  cytoskeletal	  remodeling.	  
C-­‐terminally	  of	  the	  DH/PH	  domain	  PKC	  and	  PKD	  are	  bound.	  Upregulation	  of	  AKAP-­‐Lbc	  is	  involved	  in	  the	  hypertrophic	  response	  of	  the	  heart.	  
Several	  other	  AKAP	  play	  roles	  in	  the	  physiology	  and	  pathophysiology	  in	  cardiac	  myocytes	  (for	  details	  see	  text);	  one	  example	  is	  AKAP18α.	  It	  
interacts	  with	  the	  plasma	  membrane	  as	  well	  as	  L-­‐type	  Ca2+	  channels	  (LTCC)	  and	  participates	  in	  the	  control	  of	  Ca2+	  influx.	  ET-­‐A:	  endothelin	  
receptor	  type	  A;	  AT2:	  angiotensin	  receptor	  type	  2..	  
In	  failing	  hearts	  the	  phosphorylation	  of	  regulatory	  RII	  subunits	  of	  PKA	  is	  reduced.	  Phosphorylated	  RII	  
has	  a	  similar	  affinity	  for	  the	  binding	  of	  AKAP18α,	  AKAP-­‐Lbc	  and	  mAKAP,	  dephosphorylated	  RII	  binds	  
e.g.	  AKAP-­‐Lbc	  660	  fold	  weaker	  than	  AKAP18α.	   Indeed,	   in	  failing	  hearts	  the	  interactions	  of	  PKA	  with	  
the	  AKAPs	  SPHKAP	  and	  AKAP2	  (each	  6	  fold),	  AKAP18	  (2.4	  fold)	  and	  MAP2	  (12	  fold)	  increase,	  while	  its	  
interactions	  with	  AKAP1	  (by	  50	  %)	  and	  Yotiao	  (by	  15	  %)	  decrease	  [51].	  Thus	  the	  localization	  of	  PKA	  in	  
failing	  hearts	  could	  be	  altered	  [52].	  
This	  broad	   involvement	  of	  AKAPs	  and	  their	   interactions	   in	  the	  development	  of	  cardiac	  hypertrophy	  
and	  heart	   failure	  opens	   avenues	   for	  novel	   therapeutic	   strategies.	   For	   example,	   inhibition	  of	  AKAP-­‐
PKA	   interactions	  with	   peptides	   resulted	   in	   an	   increased	   rate	   and	   amplitude	   of	   cell	   shortening	   and	  
relaxation	   compared	   to	   control	   cardiac	   myocytes	   [37].	   Small	   molecules,	   which	   inhibit	   AKAP-­‐PKA	  
interactions	  but	  at	  the	  same	  time	  activate	  PKA	  also	  increase	  contractility	  and	  may	  thus	  be	  beneficial	  
for	  the	  treatment	  of	  hypertrophy	  and	  heart	  failure	  [36].	  However,	  in	  another	  study	  peptides	  for	  the	  
disruption	   of	   AKAP-­‐PKA	   interactions	   had	   negative	   effects	   on	   chronotropy	   (frequency),	   inotropy	  
(contraction),	  and	  lusitropy	  (relaxation)	  on	  cultured	  cardiac	  myocytes	  and	  isolated	  hearts	  [35],	  and,	  
in	   line,	   prevented	   β-­‐adrenoceptor-­‐induced	   increases	   in	   L-­‐type	   Ca2+	   channel	   currents	   in	   isolated	  
cardiac	   myocytes	   [53].	   Targeting	   the	   interaction	   of	   AKAP18	   and	   PLN	   may	   lower	   the	   energy	  
expenditure	  by	  SERCA2,	  which	  is	  favorable	  in	  the	  failing	  heart	  when	  energy	  for	  contraction	  is	  limited	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[54].	  Interference	  with	  the	  RhoGEF	  activity	  of	  AKAP-­‐Lbc	  may	  interfere	  with	  α1-­‐adrenoceptor-­‐induced	  
development	  of	  cardiac	  hypertrophy.	  	  
AKAPs	  in	  kidney-­‐related	  diseases	  	  
A	   renal	   process	   that	   relies	   on	   compartmentalized	   cAMP	   signaling	   is	   AVP-­‐mediated	   water	  
reabsorption	  [34,	  55-­‐57].	   In	  renal	  collecting	  duct	  principal	  cells,	  AVP	  binds	  vasopressin	  V2	  receptors	  
(V2R)	   on	   the	   basolateral	   surface,	   leading	   to	   an	   activation	   of	   adenylyl	   cyclase	   and	   cAMP	   elevation	  
which	   is	   followed	   by	   PKA	   activation	   and	   a	   PKA-­‐dependent	   phosphorylation	   of	   the	   water	   channel	  
aquaporin-­‐2	   (AQP2)	   at	   Serine	   256.	  Under	   resting	   conditions	  AQP2	   resides	   on	   intracellular	   vesicles.	  
The	  phosphorylation	  by	  PKA	  is	  the	  key	  trigger	  for	   its	  redistribution	  into	  the	  plasma	  membrane.	  The	  
membrane	   insertion	   increases	   the	   osmotic	  water	   permeability	   of	   the	   collecting	   duct	   and	  water	   is	  
reabsorbed	   from	   primary	   urine	   (Fig.	   4)	   [56,	   58-­‐60].	   Defects	   in	   the	   mechanism	   leading	   to	   the	  
redistribution	   of	   AQP2	   cause	   nephrogenic	   diabetes	   insipidus	   (NDI),	   a	   disease	   characterized	   by	  
polyuria	   and	   polydipsia	   [56,	   61-­‐64].	   Elevated	   levels	   of	   AVP	   such	   as	   in	   late	   stages	   of	   heart	   failure	  
(NYHA	   II-­‐IV),	   in	   the	   syndrome	   of	   inappropriate	   antidiuretic	   hormone	   secretion	   (SIADH)	   or	   in	   liver	  
cirrhosis	  enhance	  the	  membrane	  association	  of	  AQP2	  and	  lead	  to	  excessive	  water	  retention	  [61,	  65-­‐
67].	  
Two	   AKAPs	   have	   been	   identified	   which	   are	   involved	   in	   the	   redistribution	   of	   AQP2:	   AKAP18δ	   and	  
AKAP220	   (Fig.	   4)	   [55,	   68-­‐70].	   Both	   AKAPs	   tether	   PKA	   to	   AQP2-­‐bearing	   vesicles	   and	   apparently	  
facilitate	   PKA	   phosphorylation	   of	   the	   channel.	   AKAP18δ	   additionally	   directly	   binds	   PDE4D3.	   Under	  
resting	  conditions,	  PDE4D3	  maintains	  a	  low	  level	  of	  cAMP	  and	  thus	  low	  PKA	  activity	  in	  the	  vicinity	  of	  
AQP2.	   This	   prevents	   an	   inappropriate	   AQP2	   phosphorylation	   and	   redistribution	   to	   the	   plasma	  
membrane	   and	   excessive	   water	   reabsorption	   under	   resting	   conditions.	   Upon	   AVP	   stimulation	   the	  
level	  of	  cAMP	  raises	  beyond	  a	  threshold	  that	  allows	  for	  PKA	  activation	  because	  local	  cAMP	  hydrolysis	  
by	   PDE4D3	   is	   saturated.	   PKA	   then	  phosphorylates	  AQP2	   inducing	   its	   translocation	   into	   the	  plasma	  
membrane	  and	  water	  reabsorption	  [71].	  	  
	   9	  
	  
Figure	   4:	   PKA-­‐triggered	   phosphorylation	   elicits	   the	   redistribution	   of	   AQP2	   into	   the	   plasma	   membrane	   of	   renal	   principal	   cells.	   AVP	  
induces	  via	  V2R	  and	  the	  G	  protein	  Gαs	  the	  activation	  of	  adenylyl	  cyclase	  and	  thus	  an	  increase	  in	  cAMP	  and	  PKA	  activity.	  The	  following	  PKA-­‐
dependent	  phosphorylation	  of	  AQP2	  on	  intracellular	  vesicles	  is	  facilitated	  by	  AKAPs	  (both	  AKAP220	  and	  AKAP18δ).	  Upon	  phosphorylation	  
AQP2	  translocates	  from	  the	  vesicles	  into	  the	  plasma	  membrane,	  resulting	  in	  an	  increased	  osmotic	  permeability	  of	  the	  collecting	  duct	  and	  in	  
the	  reabsorption	  of	  water	  from	  primary	  urine.	  Defects	  of	  this	  are	  linked	  to	  human	  diseases,	  including	  Diabetes	  insipidus,	  heart	  failure	  and	  
hyponatraemia.	  The	  system	  is	  a	  potential	  target	  for	  the	  treatment	  of	  Polycystic	  kidney	  disease	  (PKD;	  see	  text	  for	  details).	  
Targeting	   AKAP-­‐PKA	   interactions	   in	   renal	   principal	   cells	   could	   be	   a	   therapeutic	   option	   for	   the	  
treatment	  of	  diseases	  associated	  with	  excessive	  AVP-­‐mediated	  water	  reabsorption	  such	  as	  the	  ones	  
mentioned	  above.	   Indeed,	   inhibition	  of	   these	   interactions	  with	  peptides	  prevents	   the	  AVP-­‐induced	  
redistribution	  of	  AQP2	  in	  cultured	  renal	  collecting	  duct	  principal	  cells	  [34,	  55,	  57].	  
Autosomal-­‐dominant	   polycystic	   kidney	  disease	   (PKD)	   is	   caused	  by	  mutations	   in	   the	   genes	   PKD1	  or	  
PKD2,	  encoding	  polycystin-­‐1	  and	  polycystin-­‐2,	  respectively.	  The	  mutations	  result	  in	  kidney	  cysts	  and	  
ultimately	   renal	   failure.	  The	   levels	  of	   cAMP	   in	  PKD	  are	  elevated	   in	   renal	   cells	  but	  also	   in	  other	  cell	  
types	  including	  cholangiocytes	  and	  vascular	  smooth	  muscle	  cells	  [72,	  73].	  Ongoing	  clinical	  trials	  with	  
V2R	  antagonists	  and	  agonists	   (somatostatin	  analogs)	  of	  GPCRs	   that	   couple	   to	   inhibitory	  G	  proteins	  
(Gi)	   and	   lower	   cAMP	   have	   shown	   encouraging	   results.	   However,	   other	   therapeutic	   options	   are	  
conceivable.	  An	  increased	  cAMP	  level	  results	  in	  activation	  of	  PKA.	  One	  consequence	  is	  PKA-­‐catalyzed	  
hyperphosphorylation	  of	  polycystin-­‐2	  in	  PKD1.	  This	  may	  contribute	  to	  cyst	  initiation	  in	  PKD1	  patients	  
[74].	  Thus	  displacement	  of	  PKA	  from	  its	  site	  of	  action	  may	  be	  a	  therapeutic	  option.	  AKAPs	  targeting	  
PKA	  to	  such	  sites	  are	  unknown.	  So	  far	  only	  AKAP150	  has	  been	  found	  relevant	  in	  the	  development	  of	  
PKD.	   Dysregulation	   of	   a	   complex	   consisting	   of	   AKAP150,	   PKA,	   AC5/6,	   PDE4C	   and	   polycystin-­‐2	   is	  
involved	   in	   the	   pathology	   of	   PKD	   by	   controlling	   Ca2+	   entry	   into	   cells.	   Impaired	   Ca2+	   entry	   and	   the	  
consequent	  low	  intracellular	  Ca2+	  deinhibits	  Ca2+-­‐sensitive	  AC5/6	  and	  thus	  elevates	  cAMP	  [75].	  
	  
AKAPs	  in	  glucose	  homeostasis	  and	  obesity	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Glucose	   homeostasis	   is	   predominantly	   controlled	   by	   insulin,	   which	   is	   released	   from	   pancreatic	   β-­‐
cells.	   In	   diabetes	   mellitus	   type	   2	   (T2D),	   insulin	   secretion	   is	   initially	   reduced	   and	   eventually	   lost;	  
decreased	   islet	  β-­‐cell	  numbers,	   reduced	  β-­‐cell	   responsiveness	   to	  glucose	  and	   insulin	   resistance	  are	  
characteristics	  of	  T2D.	  The	  release	  of	  insulin	  is	  triggered	  by	  a	  rise	  in	  intracellular	  Ca2+.	  Ca2+	  enters	  the	  
β-­‐cells	   through	   L-­‐type	   Ca2+	   channels	   and	   initiates	   the	   fusion	   of	   insulin	   granules	   with	   the	   plasma	  
membrane	   (Fig.	   5).	   Insulin	   secretion	   is	   modulated	   by	   cAMP	   [76-­‐79].	   Studies	   of	   various	   diabetes	  
animal	  models	  as	  well	  as	  studies	  of	  cultured	  β-­‐cells	  have	  revealed	  decreased	  cAMP	   levels,	   reduced	  
AC	  and	  increased	  PDE	  expression	  [reviewed	  in	  [80]].	  In	  addition,	  AKAP-­‐PKA	  interactions	  are	  necessary	  
for	  insulin	  secretion	  and	  glucose	  homeostasis,	  as	  their	  disruption	  with	  the	  peptide	  Ht31	  (see	  below)	  
diminishes	  incretin-­‐stimulated	  insulin	  secretion	  in	  model	  cells	  and	  isolated	  pancreatic	  islets	  [32].	  	  
AKAP150	  (human	  ortholog	  AKAP79),	  AKAP18α	  and	  AKAP18ɣ	  are	  expressed	  in	  the	  pancreas	  and	  have	  
various	  functions	  in	  insulin	  release	  (Fig.	  5)	  [81-­‐83].	  While	  AKAP18α	  enhances	  glucose	  and	  glucagon-­‐
like	  peptide-­‐1	   (GLP1)-­‐stimulated	   insulin	  release,	  AKAP18ɣ	   inhibits	   this	  as	  shown	  by	  knockdown	  and	  
overexpression	   studies	   in	   rat	   insulin	   secreting	   β-­‐cells	   (RINm5F	   cells).	   In	   line,	   glucose	   stimulates	  
AKAP18α	  and	  inhibits	  AKAP18ɣ	  mRNA	  expression	  [81,	  83].	  AKAP150	  coordinates	  the	  PKA-­‐dependent	  
phosphorylation	  of	   targets	   involved	   in	   secretion	  of	   insulin	  by	   interacting	  with	   calcineurin	  and	  PKA.	  
AKAP150	  knockout	  mice	  display	   impaired	  insulin	  secretion	  and	  increased	  cAMP	  production.	  Studies	  
of	   AKAP150	   knock-­‐in	   mice	   either	   deficient	   in	   PKA	   or	   calcineurin	   binding	   suggest	   that	   calcineurin	  
anchoring	   is	  critical	   for	   the	  AKAP150-­‐controlled	   insulin	   release	   [84].	   In	  addition,	  glucose-­‐stimulated	  
cAMP	   oscillations,	   which	   are	   indispensable	   for	   insulin	   secretion,	   were	   abolished	   in	   AKAP150	  
knockout	  mice.	   Interestingly,	  Hinke	  et	  al.	   reported	   increased	   insulin	  sensitivity	   in	  skeletal	  muscle	   in	  
the	   AKAP150	   knockout	   mice,	   which	   was	   absent	   in	   the	   β-­‐islet-­‐specific	   AKAP150	   knockout	   mouse,	  
indicating	  that	  skeletal	  muscle	  selectively	  adapts	  to	  the	  absence	  of	  AKAP150	  to	  compensate	  for	  the	  
decrease	   in	   insulin.	   Thus,	   the	   interaction	   between	   AKAP150	   and	   calcineurin	   would	   be	   a	   potential	  
target	   for	   increasing	   insulin	   sensitivity	   in	   patients	   with	   diabetes	   and	   metabolic	   syndromes	   [85].	  
Conventional	   antidiabetic	   drugs	   do	   not	   directly	   target	   cAMP	   signaling.	   For	   one	   of	   the	   biguanides,	  
metformin,	   it	   was	   however	   recently	   discovered	   that	   it	   causes	   an	   accumulation	   of	   AMP	   and	   other	  
nucleotides	   that	   inhibit	  AC.	   Inhibition	  of	  adenylyl	   cyclases	   reduces	   the	  cAMP	   level	  and	  PKA	  activity	  
and	  thus	  phosphorylation	  of	  PKA	  substrates.	  This,	  in	  turn,	  blocks	  glucagon-­‐dependent	  glucose	  release	  
from	   hepatocytes	   [86].	   This	   observation	   and	   the	   established	   role	   of	   AKAPs	   and	   AKAP-­‐dependent	  
protein-­‐protein	   interactions	   in	   the	   control	   of	   glucose	   and	   insulin	   homeostasis	   suggest	   that	  
compartmentalized	   cAMP	   signaling	   is	   a	   potential	   target	   for	   pharmacological	   intervention	   to	   treat	  
diabetes.	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Figure	   5:	   AKAPs	   involved	   in	   glucose	   homeostasis	   and	   Ca2+-­‐driven	   insulin	   release	   from	   pancreatic	   β-­‐cells.	   AKAPs	   coordinate	   PKA-­‐
dependent	   target	   phosphorylation	   involved	   in	   insulin	   secretion.	   AKAP18α	   enhances	   GLP1-­‐stimulated	   insulin	   release	   by	   enhancing	  
intracellular	  Ca2+	  levels	  while	  AKAP18ɣ	  has	  the	  opposing	  effect	  (mechanism	  unknown).	  Both	  AKAP18α	  and	  AKAP150	  interact	  with	  PKA	  and	  
PP2B	  as	  well	  as	  with	  L-­‐type	  Ca2+	  channels	  (LTCC).	  Ca2+	  enters	  the	  cell	   through	  LTCC	  and	  is	  the	  main	  trigger	  for	   insulin	  release.	  Glucose	   is	  
transported	  into	  the	  cell	  and	  used	  for	  mitochondrial	  ATP	  generation.	  The	  ATP	  to	  ADP	  ratio	  controls	  ATP-­‐sensitive	  potassium	  channels	  (KATP)	  
located	  in	  the	  β-­‐cell	  plasma	  membrane:	  under	  resting	  conditions	  the	  channels	  are	  continuously	  open	  and	  thus	  potassium	  ions	  exit	  the	  cell.	  
In	   the	   presence	   of	   elevated	   glucose	   ATP	   levels	   increase	   and	   the	   consequently	   increased	   ATP	   to	   ADP	   ratio	   induces	   closure	   of	   the	   KATP	  
channel,	  causing	  a	  depolarization	  of	  the	  membrane,	  which	  promotes	  insulin	  release.	  GLP-­‐1R:	  glucagon-­‐like	  peptide-­‐1	  receptor;	  GIP/GIP-­‐R:	  
gastric	  inhibitory	  polypeptide/receptor.	  
WASP-­‐family	   verprolin	   homologous	   protein	   1	   (WAVE-­‐1)	   regulates	   actin	   cytoskeleton	   dynamics,	  
apoptosis	   and	   glycolysis.	   It	   functions	   as	   an	   AKAP	   and	   a	   WAVE-­‐1-­‐coordinated	   protein	   complex	  
consisting	  of	  Bcl-­‐2	  antagonist	  of	  cell	  death	   (BAD),	  glucokinase	   (GK,	  Hexokinase	  D),	  PKA	  and	  protein	  
phosphatase	   1	   (PP1)	   is	   involved	   in	   glucose-­‐driven	   mitochondrial	   respiration	   in	   the	   liver:	   PKA	   is	  
targeted	  via	  WAVE-­‐1	   to	  mitochondria,	  phosphorylates	  and	  thereby	   inactivates	  BAD,	  which	   leads	   to	  
dissociation	  of	  the	  protein	  complex;	  PP1	  instead	  activates	  BAD	  via	  dephosphorylation	  [87,	  88].	  As	  GK	  
only	  binds	  to	  active	  BAD,	  the	  phosphorylation	  status	  of	  BAD	  determines	  the	  binding	  of	  the	  glycolysis	  
enzyme	  GK	  to	  the	  above-­‐mentioned	  complex.	  Mice	  either	  BAD-­‐deficient	  or	  expressing	  a	  BAD	  variant	  
which	   cannot	   be	   phosphorylated	   show	   abnormal	   glucose	   homeostasis	   and	   glucose	   tolerance	   in	  
correlation	  with	  diminished	  GK	  activity.	  GK	  couples	  blood	  glucose	  level	  changes	  to	  insulin	  release	  for	  
maintaining	  glucose	  homeostasis	  and	  the	  pathophysiology	  of	  T2D	   is	   linked	  to	  both	  gain-­‐of-­‐function	  
and	   loss-­‐of-­‐function	  mutations	   in	   the	  GK-­‐encoding	  gene	   [89,	  90].	   In	  addition,	  GK	   inactivity	  or	  over-­‐
expression	  disturbs	  glucose	  uptake	  and	  has	  been	  shown	  to	  be	  defective	  in	  T2D	  patients	  [90,	  91].	   In	  
addition,	   GK	   activation	   has	   been	   recognized	   as	   a	   treatment	   strategy	   for	   T2D	   and	   targeted	  
pharmacologically	   by	   GK	   activating	   chemical	   compounds	   such	   as	   piragliatin,	   leading	   to	   decreased	  
hepatic	  glucose	  output	  in	  T2D	  patients	  [92].	  As	  BAD	  is	  phosphorylated	  in	  an	  AKAP-­‐dependent	  manner	  
by	  PKA,	  targeting	  the	  PKA-­‐WAVE-­‐1	  interaction	  within	  the	  protein	  complex	  potentially	   induces	  more	  
BAD	   activity	   and	   thus	   ultimately	   increases	   GK	   activity.	   	   Influencing	   GK	   activity	   via	   targeting	   the	  
WAVE-­‐1/BAD/GK/PKA/PP1	  protein	  assembly	  might	  be	  beneficial	   in	  reestablishing	  glucose	  uptake	   in	  
T2D	  patients.	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Diabetes	   and	   obesity	   are	   associated	   with	   deregulated	   fat	   metabolism;	   for	   example,	   triglycerides	  
accumulate	  in	  the	  liver	  of	  late	  stage	  Diabetes	  patients	  causing	  fatty	  liver.	  Pidoux	  et	  al.	  identified	  optic	  
atrophy	  1	  (OPA1)	  as	  a	  dual-­‐specific	  AKAP	  forming	  a	  complex	  with	  PKA	  and	  perilipin	  on	  lipid	  droplets	  
[93].	  Lipid	  droplets	  are	  characteristic	  cytosolic	  compartments	  of	  adipocytes	  and	  serve	  as	  triglyceride	  
and	   cholesterol	   storages	   [94].	   Peptides	   interfering	   with	   AKAP-­‐PKA	   interactions	   inhibit	   OPA1-­‐
mediated	   anchoring	   of	   PKA	   to	   the	   lipid	   droplet	   surface	   and	   PKA-­‐dependent	   phosphorylation	   of	  
perilipin	  and,	  thereby,	  adrenergic	  stimulation	  of	  lipolysis	  [93,	  95].	  Thus	  targeting	  OPA1	  may	  lower	  the	  
triglyceride	   load	   in	   Diabetes	   patients.	   AKAP149	   (AKAP1,	   D-­‐AKAP1)	   was	   found	   to	   be	   the	   most	  
abundant	  AKAP	  in	  adipocytes	  [96].	  A	  fourfold	  reduction	  of	  AKAP149	  gene	  expression	  was	  detected	  in	  
adipose	   tissue	   of	   obese	   patients	   [95-­‐97].	   AKAP1	   localizes	   predominantly	   type	   II	   PKA	   and	   other	  
interaction	  partners	  to	  the	  outer	  mitochondrial	  membrane	  (reviewed	  in	  [98]).	  AKAP1	  associates	  with	  
mRNAs,	   e.g.	   encoding	  mitochondrial	   ATP	   synthase	   F0-­‐f	   subunit,	  manganese	   superoxide	   dismutase	  
and	  steoridogenic	  acute	  regulator,	   localizing	  them	  close	  to	  the	  outer	  mitochondrial	  membrane	  and	  
suggesting	  an	  implication	  in	  steroidogenesis	  [99,	  100].	  Of	  note,	  AKAP1	  binds	  lipoprotein	  lipase	  (LPL)	  
mRNA	   and	   thereby	   inhibits	   its	   translation,	   suggesting	   that	   reduced	   AKAP1	   levels	   in	   obesity	  might	  
cause	  an	  increase	  in	  LPL	  and	  thus	  increased	  LPL-­‐dependent	  adipose	  tissue	  lipogenesis	  and	  fatty	  acid	  
uptake	  [95].	  Thus	  interference	  with	  AKAP1-­‐mRNA	  interactions	  may	  be	  a	  therapeutic	  strategy	  for	  the	  
treatment	  of	  obesity.	  
AKAPs	  in	  sickle	  cell	  disease	  
Sickle	   cell	   disease	   (sickle	   cell	   anemia)	   is	   a	   hereditary	   disorder	   that	   affects	   hemoglobin	   and	   is	  
accompanied	  by	  severe	  pain	  attacks.	  A	  sickle-­‐cell	  crisis	  can	  be	  initiated	  by	  adhesion	  of	  red	  blood	  cells	  
to	   the	   vascular	  wall	   leading	   ultimately	   to	   vasoocclusion.	   Red	   blood	   cell	   deformability	   is	   crucial	   for	  
maintaining	   normal	   blood	   flow	   and	   changes	   in	   deformability	   occur	   e.g.	   upon	   mechanical	   stress.	  
cAMP	   and	   Ca2+-­‐dependent	   signaling	   pathways	   play	   a	   role	   in	   the	   regulation	   of	   red	   blood	   cell	  
membrane	  properties	  related	  to	  aggregability	  and	  filterability	  [101].	  	  
Sickle	  cell	  red	  blood	  cells	  do	  not	  only	  contain	  more	  than	  fourfold	  higher	  cAMP	  levels	  than	  unaffected	  
red	  blood	  cells	  [102],	  but	  also	  acquire	  a	  PKA-­‐dependent	  adhesion	  mechanism	  by	  which	  they	  bind	  to	  
the	  vascular	  wall.	  Cytoadherence	  of	  red	  blood	  cells	  to	  the	  endothelial	  basal	  lamina	  via	  the	  basal	  cell	  
adhesion	  molecule/Lutheran	  (BCAM/Lu)	  receptor	  is	  important	  in	  vasoocclusive	  episodes	  of	  sickle	  cell	  
disease	  [103,	  104].	  It	  is	  well	  established	  that	  cAMP	  is	  crucial	  for	  BCAM/Lu	  receptor	  activation	  [102].	  
However,	   the	   involvement	   of	   AKAPs	   as	   well	   as	   their	   assistant	   function	   in	   BCAM/Lu	   receptor	  
phosphorylation	  has	  only	  recently	  been	  uncovered	  (Fig.	  6).	  AKAPs	  are	  present	  in	  sickle	  red	  blood	  cell	  
plasma	   membranes	   [105].	   By	   using	   the	   stearate-­‐coupled	   AKAP-­‐PKA	   disruptor	   peptide	   Ht31,	  
Maciaszek	  et	  al.	  demonstrated	  the	  requirement	  of	  intact	  AKAP-­‐PKA	  interactions	  in	  normal	  as	  well	  as	  
sickle	  cell	  disease	  red	  blood	  cell	  adhesion	  [105].	  This	  finding	  may	  lead	  to	  an	  alternative	  strategy	  for	  
the	  reduction	  of	  vasoocclusion	   in	  sickle	  cell	  disease,	  namely	  disruption	  of	  AKAP-­‐PKA	  interactions	  or	  
displacement	  of	  the	  relevant	  AKAP/s	  (not	  identified	  yet)	  from	  its	  cognate	  location.	  An	  alternative	  to	  
the	   current	   treatment	   with	   Hydroxyurea	   is	   highly	   desirable	   as	   this	   can	   cause	   severe	   side	   effects.	  
Hydroxyurea	   is	   used	   to	  prevent	  painful	   episodes	   and	   to	   reduce	   the	  need	   for	  blood	   transfusions	   in	  
sickle	  cell	  disease	  but	  is	  also	  used	  for	  the	  treatment	  of	  skin	  and	  other	  cancers.	  Hydroxyurea	  reduces	  
BCAM/Lu	   receptor	   expression	   and	   interferes	  with	   the	   interaction	   between	   the	   BCAM/Lu	   receptor	  
and	  laminin,	  a	  constituent	  of	  the	  endothelial	  basal	  lamina	  [106].	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Figure	   6:	  The	   function	   of	   AKAPs	   in	   abnormal	   adhesion	   of	   and	   vaso-­‐occlusion	   by	   erythrocytes	   as	   characteristic	   features	   of	   sickle	   cell	  
disease	  (SCD).	  Epinephrine	  induces	  GPCR-­‐mediated	  activation	  of	  AC,	  increased	  intracellular	  cAMP	  levels	  and	  thus	  activation	  of	  PKA	  as	  well	  
as	  Epac.	  Epacs	  promote	  the	  talin-­‐dependent	  activation	  of	  integrin	  α4β1	  receptors	  which	  serve	  as	  a	  bridge	  between	  the	  actin	  cytoskeleton	  
and	   the	   extracellular	  matrix	   (ECM)	   around	   and	   below	   the	   basal	   endothelium,	   e.g.	   by	   recognizing	   VCAM-­‐1	   on	   the	   surface	   of	   the	   basal	  
endothelium.	  AKAP-­‐facilitated	   PKA	  phosphorlyation	   assists	   the	   adhesion	  of	   extracellular	   Bcam/Lu	   to	   Lamininα5.	   SCD	  erythrocytes	   show	  
increased	  cAMP	  levels,	  upregulated	  expression	  of	  integrins	  as	  well	  as	  Bcam/Lu	  receptors.	  These	  observations	  are	  in	  line	  with	  an	  increased	  
affinity	  of	   the	  cellular	  membrane	   receptors	   for	   laminin	  and	  ECM	  proteins	   in	  SCD	  erythrocytes	  ultimately	  enhancing	   the	  adhesion	  of	   red	  
blood	  cells	  to	  the	  vascular	  wall	  and	  vaso-­‐occlusion.	  	  	  
AKAPs	  in	  cancer	  
Cancer	   cells	   acquire	   the	  ability	   to	   increase	  proliferation,	  which	   is	  associated	  with	  upregulated	  Ras-­‐
Raf-­‐MEK-­‐ERK	   signaling,	   e.g.	   caused	   by	   mutations	   in	   the	   gene	   encoding	   BRAF	   [107].	   Cancer	   cell	  
proliferation	   can	   be	   controlled	   by	   the	   interplay	   between	   the	   Ras-­‐Raf-­‐MEK-­‐ERK	   pathway	   and	   the	  
cAMP/PKA	   system	   and	   involves	   scaffolding	   proteins	   for	   the	   local	   and	   temporal	   control	   of	   the	  
crosstalk	  including	  AKAPs.	  AKAP-­‐Lbc	  is	  not	  only	  involved	  in	  cardiac	  myocyte	  hypertrophy	  but	  also	  has	  
a	  role	   in	  cancer.	   It	  mediates	  cAMP/PKA	  phosphorylation	  of	  kinase	  suppressor	  of	  Raf	  (KSR)	  and	  thus	  
the	  subsequent	  increase	  of	  MEK	  and	  ERK	  activity	  through	  a	  signalosome	  composed	  of	  AKAP-­‐Lbc,	  PKA,	  
Raf	   and	   KSR1	   [108].	   The	   consequence	   is	   a	   proliferative	   effect	   (Fig.	   7).	   Targeting	   the	   AKAP-­‐Lbc	  
signalosome	  may	  therefore	  be	  antiproliferative.	  	  
At	   least	   three	   splice	   variants	   of	   AKAP-­‐Lbc	   have	   been	   identified.	   Only	   full-­‐length	   AKAP-­‐Lbc	   (2813	  
amino	   acids)	   has	   a	   PKA	   anchoring	   domain	   [22,	   109,	   110].	   A	   single	   nucleotide	   polymorphism	  
(Lys526Gln)	   was	   associated	   with	   increased	   familial	   breast	   cancer	   risk	   in	   genome-­‐wide	   association	  
studies.	  The	  polymorphism	  is	  not	  located	  in	  any	  DNA	  region	  that	  encodes	  a	  defined	  domain	  of	  AKAP-­‐
Lbc;	  it	  may	  alter	  the	  secondary	  structure	  of	  the	  protein	  [111].	  Overexpression	  of	  AKAP-­‐Lbc	  is	  linked	  to	  
uterine	  leiomyoma	  [112].	  All	  AKAP-­‐Lbc	  isoforms	  possess	  a	  RhoGEF	  domain	  [22,	  113].	  The	  truncated	  
form	  of	  AKAP-­‐Lbc	  known	  as	  Onco-­‐Lbc	  consists	  of	  the	  RhoGEF	  domain	  and	  70	  N-­‐terminal	  amino	  acids 
(amino	   acids	   1922-­‐2346	   of	   AKAP-­‐Lbc).	  Onco-­‐Lbc	  was	   identified	   in	  material	   from	  myeloid	   leukemia	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patients	   [114]	   and	   induces	   Rho-­‐dependently	   cell	   cycle	   progression	   [115],	   the	   formation	   of	   actin	  
stress	   fibers	   as	  well	   as	   the	   assembly	  of	   focal	   adhesions	   in	   fibroblasts	   [113,	   116].	   The	   third	   form	   is	  
termed	   Proto-­‐Lbc	   and	   consists	   of	   the	   Rho	  GEF	   domain	   plus	   an	   extended	   C-­‐terminal	   region	   that	   is	  
absent	  in	  Onco-­‐Lbc	  [117]	  (amino	  acids	  1922-­‐2813	  of	  AKAP-­‐Lbc).	  Proto-­‐Lbc	  is	  expressed	  in	  testis	  and	  
estrogen-­‐sensitive	   tissues.	   While	   the	   RhoGEF	   domain	   of	   full-­‐length	   AKAP-­‐Lbc	   underlies	   tight	  
regulation	   by	   PKA	   and	   homodimerization	   [118],	   the	   two	   truncated	   versions	   possess	   constitutively	  
active	   RhoGEF	   domains	   that	   increase	   Rho	   activity	   [113].	   Activated	   Rho	   is	   involved	   as	   a	  molecular	  
switch	   in	   numerous	   cellular	   processes,	   e.g.	   cytoskeletal	   dynamics,	   cell	   polarity	   and	  motility	   [119].	  
Activation	   of	   RhoA	   by	   RhoGEFs	   requires	   direct	   protein-­‐protein	   interactions.	   Thus	   targeting	   the	  
interaction	  of	   the	  RhoGEF	  domain	  of	   the	  AKAP-­‐Lbc	  variants	  with	  RhoA	   in	  cancer	  cells	  may	  have	  an	  
antiproliferative	  effect.	  	  
Of	   note,	   cytoskeletal	   regulation	   as	   well	   as	   cell	   migration	   are	   PKA-­‐dependent	   processes	   and	  
particularly	   interesting	   with	   regard	   to	   physiological	   changes	   leading	   to	   tumor	   cell	   invasion	   and	  
metastatic	   cell	   spreading.	   One	   aspect	   to	   consider	   is	   the	   dynamic	   regulation	   of	   PKA	   by	   integrin-­‐
mediated	  cell	  adhesion	   to	  extracellular	  matrix	   (ECM).	  Furthermore,	   PKA	  activity	   is	   required	   for	  key	  
activation	  processes	  in	  cell	  migration	  and	  cytoskeletal	  organization,	  e.g.	  Rac	  and	  Cdc42	  activation	  and	  
the	  assembly	  of	  actin	  filament	  assembly,	  reviewed	  in	  [120].	  cAMP/PKA	  signaling	  is	  spatially	  regulated	  
by	  AKAP-­‐anchoring	  of	  PKA	  with	  various	  proteins	  of	  the	  actin	  cytoskeleton,	  an	  example	  of	  which	  is	  the	  
PKA	   substrate	   Vasodilator-­‐stimulated	   phosphoprotein	   (VASP),	   being	   a	   critical	   player	   in	   actin	  
remodeling	  and	  actin-­‐based	  cell	  motility	  [121].	   
Several	  AKAPs	  are	  associated	  with	  cancer,	  in	  particular	  through	  their	  control	  over	  mitosis	  and	  the	  cell	  
cycle	  and	  thus	  cancer	  progression	  [reviewed	  in	  [7,	  122-­‐124]].	  For	  example,	  an	  increased	  risk	  of	  breast	  
cancer	   is	   linked	   with	   single	   nucleotide	   polymorphisms	   in	   AKAP9	   and	   D-­‐AKAP2.	   AKAP9	   promotes	  
colorectal	  cancer	  cell	  proliferation,	  migration	  and	  invasion	  and	  has	  been	  shown	  to	  be	  upregulated	  in	  
these	  cells	  [125].	  In	  addition,	  the	  expression	  of	  the	  tumor	  suppressor	  Gravin	  and	  its	  rodent	  ortholog	  
Src-­‐suppressed	   C	   kinase	   substrate	   (SSeCKS)/AKAP12	   [24]	   [recently	   reviewed	   in	   detail	   [124]]	   is	  
suppressed	   in	   various	   solid	   tumors	   [126-­‐128],	   partly	   through	   hypermethylation	   of	   the	   gravin	  
promoter	  [129-­‐131].	  Gravin	  was	  thought	  to	  inhibit	  Src	  activity,	  but	  has	  recently	  been	  shown	  to	  rather	  
sequester	   Src	   to	   reduce	  mitogenic	   signaling	   [132].	   The	   assembly	  of	  Gravin,	   PKC	   and	   inactive	   Src	   is	  
anchored	  to	  caveolin-­‐rich	  lipid	  rafts	  and	  thereby	  removes	  Src	  from	  both	  focal	  adhesion	  kinase	  (FAK)-­‐
associated	  adhesion	  and	  PKC-­‐dependent	  activation	  of	  the	  Ras-­‐Raf-­‐MEK-­‐ERK	  cascade.	  In	  the	  absence	  
of	   Gravin,	   Src	   kinase	   is	   active	   and	   induces	   PKC-­‐mediated	   activation	   of	   ERK	   signaling	   along	   with	  
increased	   proliferation,	   unregulated	   cell	   growth	   and	   secretion	   of	  matrix	  metalloproteinases	   [133];	  
focal	  adhesions	  are	  reduced	  due	  to	  active	  FAK	  leading	  to	  cell	  migration	  and	  invasion	  (Fig.	  7).	  Loss	  of	  
Gravin	   and	   the	   degree	   of	   its	   decreased	   expression	   correlate	   with	   poor	   prognosis,	   e.g.	   in	   acute	  
myeloid	  leukemia	  [134].	  Increased	  hypermethylation	  of	  the	  gravin	  promoter	  coincides	  with	  increased	  
metastasis	   and	   Gravin	   has	   been	   suggested	   as	   a	   cancer	   progression	   biomarker.	  Whether	   selective	  
elevation	  of	  Gravin	  protein	  abundance	  would	  be	  an	  option	  for	  cancer	  treatment	  is	  unclear	  so	  far,	  but	  
in	   the	   context	   of	   the	   Gravin-­‐PKC-­‐Src	   assembly	   a	   stabilization	   of	   the	   protein	   complex	   would	   be	  
favorable.	  	  
The	  testis-­‐specific	  AKAP4	  is	  important	  in	  sperm	  motility	  [135,	  136].	  AKAP4	  is	  aberrantly	  expressed	  in	  
various	  malignant	  tissues	  [137].	  Its	  expression	  triggers	  humoral	  immune	  responses	  in	  ovarian	  cancer	  
and	   is	  associated	  with	  malignant	  properties	  of	   cervical,	  breast	  and	  prostate	  cancer	   [138].	  AKAP4	   is	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currently	   analyzed	   as	   a	   potential	   target	   for	   cervical	   cancer	   immunotherapy	   [139,	   140].	   The	   strong	  
expression	  of	  AKAP4	  in	  multiple	  myeloma	  led	  to	  its	  classification	  as	  cancer	  testes	  antigen	  [137].	  
Taken	   together,	   cancer-­‐related	   AKAP	   interactions	   are	   worth	   validating	   as	   possible	   targets	   for	  
pharmacological	  interventions.	  
	  
Figure	  7:	  Function	  of	  selected	  AKAPs	  in	  cancer.	  Growth	  factors	  on	  the	  one	  hand	  activate	  the	  Ras-­‐Raf-­‐MEK-­‐ERK	  cascade	  via	  receptor	  tyrosin	  
kinases	  (RTK)	  and	  the	  AKAP-­‐Lbc-­‐anchored	  complex	  consisting	  of	  PKA,	  RAF,	  KSR	  and	  MEK,	  and	  on	  the	  other	  hand	  induce	  the	  production	  of	  
cAMP	  and	  increase	  PKA	  activity	  via	  GPCR	  signalling.	  Upon	  Raf	  activation,	  AKAP-­‐Lbc-­‐anchored	  PKA	  phosphorylates	  KSR	  and	  thus	  induces	  a	  
conformational	  change	  of	  MEK,	  resulting	  in	  the	  activation	  of	  ERK,	  which	  in	  turn	  enhances	  cell	  cycle	  progression	  and	  cellular	  growth.	  In	  case	  
of	  AKAP-­‐Lbc	  upregulation	  such	  as	   in	  cancer	  tissue	  the	  progression	  of	  tumor	  growth	  is	  promoted	  by	  the	  subsequent	  increase	  of	  MEK	  and	  
ERK	  activity	  through	  the	  AKAP-­‐Lbc/	  PKA/	  Raf/	  KSR1	  signalosome.	  The	  assembly	  of	  the	  AKAP	  Gravin	  with	  PKC	  and	  Src	  removes	  Src	  from	  both	  
focal	   adhesion	   kinase	   (FAK)-­‐associated	   cell	   migration	   and	   PKC-­‐dependent	   activation	   of	   the	   Ras-­‐Raf-­‐MEK-­‐ERK	   cascade.	   Gravin	   is	   down-­‐
regulated	   in	   cancer,	   hence	   its	   absence	   supports	   Ras-­‐Raf-­‐MEK-­‐ERK	   signalling	   as	   well	   as	   the	   disassembly	   of	   focal	   adhesions	   (as	   FAK	   is	  
consequently	   bound	   by	   the	   available	   Src)	   resulting	   in	   increased	   cell	   motility	   and	   metastasis.	   	   PP2A:	   protein	   phosphatase	   2A;	   PIP:	  
phosphatidylinositolphosphate.	  
AKAPs	  in	  the	  immune	  system	  
The	  current	  knowledge	  about	  the	  role	  of	  AKAPs	  in	  the	  immune	  system	  is	  mainly	  restricted	  to	  T	  cells	  
and	  HIV	  infection.	  In	  T	  cells	  of	  HIV	  patients,	  the	  levels	  of	  cAMP	  and	  PKA	  type	  I	  activity	  are	  elevated	  
[33,	  141-­‐143],	  and	  cAMP	  inhibits	  T	  cell	  receptor	  (TCR)-­‐induced	  T	  cell	  proliferation	  [144].	  In	  line,	  TCR-­‐
induced	   T	   cell	   activation	   is	   inhibited	   e.g.	   by	   GPCR-­‐mediated	   signaling	   via	   prostaglandin	   E2	   (PGE2),	  
which	  signals	  amongst	  others	  through	  the	  GS/adenylyl	  cyclase	  system.	  	  
A	  few	  AKAPs	  have	  been	  identified	  in	  T	  cells	  (recently	  reviewed	  in	  [145]).	  The	  mitochondrial	  AKAP1	  is	  
indispensable	   for	   efficient	   HIV	   replication	   [146,	   147]	   through	   its	   interaction	   with	   HIV-­‐1	   reverse	  
transcriptase,	   the	   enzyme	   converting	   single-­‐strand	   viral	   RNA	   into	   double-­‐strand	   DNA	   for	   the	  
integration	   into	   the	   host	   genome.	   Thus	   the	   interaction	   of	   AKAP1	   with	   HIV	   reverse	   transcriptase	  
constitutes	  a	  potential	  target	  for	  the	  pharmacological	  inhibition	  of	  early	  viral	  replication.	  
Ezrin,	  a	  member	  of	  the	  ERM	  family	  of	  proteins,	  is	  a	  dual-­‐specific	  AKAP	  that	  binds	  F-­‐actin	  and	  links	  the	  
cytoskeleton	  and	  the	  plasma	  membrane.	  A	  complex	  comprising	  Ezrin,	  PKA	  type	  I	  and	  C-­‐terminal	  Src	  
kinase	  (Csk)	  is	  present	  in	  lipid	  rafts	  of	  T	  cell	  plasma	  membranes	  in	  close	  proximity	  to	  the	  TCR	  during	  T	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cell	   activation	   [148].	   PGE2	   production	   is	   enhanced	   in	   response	   to	   continuous	   antigen	   presentation	  
such	  as	  in	  HIV	  infection	  and	  leads	  to	  PGE2-­‐induced	  stimulation	  of	  AC	  and	  subsequent	  PKA	  activation.	  
Ezrin-­‐anchored	  PKA	  guides	  the	  phosphorylation	  of	  Csk	  that	   inhibits	  T	  cell	  proliferation	  and	  function	  
(recently	  reviewed	  in	  [149]).	  Hyperactivation	  of	  the	  PKA-­‐Csk	  pathway	  is	  involved	  both	  in	  HIV	  infection	  
and	   in	   murine	   AIDS	   [142,	   150].	   The	   disruption	   of	   the	   PGE2-­‐cAMP-­‐PKA	   pathway	   with	   peptides	  
targeting	  AKAP-­‐PKA	  interactions	  causes	  an	  increase	  in	  effector	  T	  cell	  function,	  e.g.	  reduced	  sensitivity	  
to	  PGE2-­‐dependent	  T	  cell	  inhibition.	  Mice	  overexpressing	  the	  AKAP-­‐PKA	  disruptor	  RIAD	  had	  improved	  
resistance	   to	   murine	   leukemia	   virus-­‐induced	   immunodeficiency,	   in	   line	   with	   hyperactive	   PKA-­‐Csk	  
signaling	  [151].	  Ezrin	  knockdown	  in	  cultured	  T	  lymphoblasts	  enhances	  HIV-­‐1-­‐induced	  cell-­‐cell	  fusion,	  
described	  as	   syncytium	   formation	   that	   assists	   in	   spreading	  of	   the	   virus	   [152].	   Thus	   Ezrin	   limits	   the	  
spread	  of	  HIV-­‐1	  by	  suppressing	  membrane	  fusion	  events.	  	  
As	   AKAP1	   is	   implicated	   in	   HIV	   early	   replication	   and	   Ezrin	   in	   HIV	   transmission	   through	   cell	   fusion	  
disruption	   of	   AKAP-­‐dependent	   protein-­‐protein	   interactions	   and/or	   the	   displacement	   of	   a	   defined	  
AKAP	  from	  its	  cognate	  cellular	  location	  may	  be	  a	  therapeutic	  option	  for	  the	  treatment	  of	  AIDS.	  With	  
the	   inhibition	   of	   RI-­‐AKAP	   interactions	   in	   a	  murine	  AIDS	  model	   first	   attempts	   have	   been	   successful	  
already	  [153].	  
	  
Figure	  8:	  AKAP-­‐dependent	  processes	  involved	  in	  T	  cell	  activation.	  PGE2-­‐induced	  GPCR	  activation	  signals	  through	  the	  Gαs/AC	  system	  and	  
leads	   to	   subsequent	   PKA	   activation.	   The	   cAMP-­‐PKA	  pathway	   is	   involved	   in	   the	   regulation	   and	  modulation	  of	   immune	   responses.	   Ezrin-­‐
anchoring	   in	   lipid	   rafts	   (dark	   grey	   plasma	   membrane	   region)	   positions	   PKA	   close	   to	   its	   substrate	   Csk	   (C-­‐terminal	   Src	   kinase).	   Csk	  
phosphorylation	  by	  PKA	  in	  the	  vicinity	  of	  TCR	  results	  in	  the	  inhibition	  of	  Lck	  in	  line	  with	  inhibited	  CD4(+)	  T	  cell	  proliferation	  and	  function.	  
CD43	   regulates	  multiple	   T-­‐cell	   functions,	   including	   T-­‐cell	   activation,	   proliferation,	   apoptosis,	   and	  migration	   by	   linking	   Ezrin	   to	   the	   actin	  
cytoskeleton.	  Hyperactive	  cAMP/Csk	  signaling	   is	   involved	   in	  HIV	   infection	  and	  acquired	  T	  cell	  deficiency.	   Lck:	  Src	   family	  tyrosine	  kinases;	  
PAG:	   phosphoprotein	   associated	  with	   glycosphingolipid-­‐enriched	  membrane	  microdomains;	   EBP50:	   ERM	   (Ezrin/Radixin/Moesin)-­‐binding	  
phosphoprotein	  50.	  	  
AKAPs	  have	  also	  been	  identified	  in	  dendritic	  cells,	  the	  major	  antigen	  presenting	  cells	  of	  the	  immune	  
system	  [154].	  Dendritic	  cell	  maturation	  and	  activity	  is	  regulated,	  amongst	  others,	  by	  PKA	  and	  cAMP	  
[155].	  Human	  dendritic	  cells	  express	  AKAP79,	  AKAP1,	  AKAP95,	  AKAP-­‐Lbc	  and	  Ezrin;	  their	  expression	  
upon	   maturation	   from	   a	   monocyte	   to	   a	   mature	   dendritic	   cell	   is	   differentially	   regulated:	   The	  
	   17	  
expression	  of	  AKAP95	  and	  Ezrin	  does	  not	  change,	  but	  that	  of	  AKAP79,	  AKAP1	  and	  AKAP-­‐Lbc	  increases	  
and	   this	   is	   accompanied	  by	   a	   1.8-­‐fold	   increase	  of	   RIIα	  protein	   expression.	   Indeed,	   optimal	   antigen	  
presentation	  by	  dendritic	  cells	  and	  T	  cell	  activation	  requires	  PKA	  anchoring	  [154,	  156].	  
Chronic	  obstructive	  pulmonary	  disease	  (COPD)	   is	  an	  airway	  disease	   involving	  chronic	   inflammation,	  
airway	  obstruction,	   fibrosis	  and	  chronic	  bronchitis	   [157].	  Secretion	  of	   inflammatory	  mediators	  such	  
as	  Interleukin	  8	  (IL-­‐8)	  contributes	  to	  the	  pathogenesis	  [158].	  The	  mRNA	  expression	  of	  IL-­‐8	  positively	  
correlates	   with	   COPD	   progression	   in	   lung	   biopsies	   [159].	   Cigarette	   smoke	   represents	   a	  major	   risk	  
factor	   of	   COPD	   and	   induced	   IL-­‐8	   release	   from	   inflammatory	   cells,	   structural	   lung	   cells	   and	   airway	  
smooth	  muscle	   (ASM)	   cells	   [160].	   cAMP	  compartmentalization	   is	   involved	   in	   important	   features	  of	  
COPD	   such	   as	   inflammation	   and	   airway	   remodeling.	   ASM	   cells	   are	   important	   players	   in	   these	  
processes	   (recently	   reviewed	   in	   [161]).	   They	   switch	   phenotype	   between	   a	   proliferative	   and	  
contractile	  state	  upon	  stimulation,	  e.g.	  by	  growth	  factors.	  This	  process	  involves	  PKA	  and	  Epac	  [162]	  
that	   apparently	   act	   synergistically	   [163,	   164].	   The	   activation	   of	   either	   Epac	   or	   PKA	   decreased	  
cigarette	  smoke	  extract-­‐induced	  IL-­‐8	  mRNA	  expression	  and	  IL-­‐8	  release	  from	  human	  ASM	  cells	  by	  a	  
mechanism	   involving	  ERK	  and	  NFƙB	   signaling	   [162].	  The	  expression	  of	  AKAP5,	  AKAP12	  and	  Ezrin	   in	  
human	  ASM	  cells	  [165]	  suggests	  that	  these	  AKAPs	  are	  of	  importance	  in	  ASM	  cell	  responses.	  As	  there	  
is	   no	   curative	   treatment	   existing	   for	   COPD,	   the	   medical	   need	   for	   pharmacological	   intervention	   is	  
high.	   Local	   PKA	   signaling	   might	   be	   an	   appropriate	   pharmacological	   target	   for	   anti-­‐inflammatory	  
therapy	  of	  COPD	  [162].	  	  
AKAPs	  in	  neurological	  processes	  and	  disorders	  
Learning	  and	  memory	  formation	  are	  based	  on	  long-­‐term	  potentiation	  (LTP)	  and	  long-­‐term	  depression	  
(LTD)	   that	  define	   synaptic	  plasticity,	   the	   strength	  of	   synaptic	   transmission	   [166,	  167].	   LTD	  and	  LPD	  
have	   been	   extensively	   studied	   in	   the	   hippocampus.	   Many	   of	   the	   studies	   linked	   LTD	   and	   LTP	   to	  
receptors	  which	   are	   phosphorylated	  by	   PKA	   [167],	   in	   particular	  AMPA-­‐	   and	  NMDA-­‐type	   glutamate	  
receptors.	   AKAP-­‐PKA	   complexes	   play	   prominent	   roles	   in	   synaptic	   plasticity	   by	   modulating	   Ca2+	  
influxes	   into	   hippocampal	   neurons	   through	   these	   receptors	   [9,	   168-­‐171].	   Disturbances	   in	   the	  
modulation	  of	  synaptic	  strengths	  are	  a	  common	  phenomenon	  in	  pathological	  conditions	  and	  disease.	  
Neuronal	  AKAP150	  is	  the	  platform	  for	  different	  multiprotein	  complexes	  (recently	  reviewed	  in	  [124]).	  
One	  complex	  formed	  by	  AKAP150,	  PP2B/calcineurin,	  PKC	  and	  PKA	  modulates	  diverse	  functions	  at	  the	  
post-­‐synaptic	  membrane	  [172-­‐175].	  AKAP150-­‐dependent	  and	  PKA-­‐mediated	  phosphorylation	  of	  the	  
AMPA	  receptor	  GluA1	  subunit	  triggers	  the	  insertion	  of	  the	  receptor	  into	  the	  post-­‐synaptic	  membrane	  
during	   LTD,	   while	   dephosphorylation	   through	   AKAP150-­‐bound	   calcineurin	   has	   the	   opposite	   effect	  
(Figure	  9)	  [175].	  	  
AKAP-­‐PKA	  interactions	  are	  also	  associated	  with	  the	  development	  of	  inflammatory	  pain	  and	  increased	  
sensitivity	   of	   pain	   [176].	   Sensitivity	   to	   pain	   involves	   phosphorylation	   and	   activation	   of	   Transient	  
Receptor	   Potential	   Vanilloid	   1	   (TRPV1)	   by	   PKA	   (Figure	   9).	   AKAP150	   is	   implicated	   in	   the	  
phosphorylation	  of	  TRPV1	  by	  PKA	  [177,	  178].	  In	  mice	  lacking	  the	  PKA	  binding	  site	  of	  AKAP150	  PGE2-­‐
induced	  thermal	  hyperalgesia	   is	   inhibited,	  suggesting	  that	   the	  AKAP150-­‐PKA	   interaction	   is	  essential	  
for	   TRPV1	   function	   [176].	   Calcineurin	   dephosphorylates	   TRPV1	   independently	   of	   its	   anchoring	   by	  
AKAP150	  [179].	  The	  PKA-­‐dependent	  reduction	  of	  TRPV1	  desensitization	  has	  been	  suggested	  to	  have	  
a	  facilitator	  purpose	  during	  inflammation	  periods	  marked	  by	  continuous	  channel	  activation	  and	  being	  
involved	  in	  chronic	  pain	  [180].	  In	  inflammatory	  processes	  the	  disruption	  of	  PKA	  anchoring	  to	  TRPV1	  
may	  be	  a	  strategy	  for	  altering	  the	  effects	  of	  chronic	  TRPV1	  activation.	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The	  AKAP	  Neurobeachin	  (NBEA)	  was	  identified	  as	  a	  candidate	  gene	  for	  autism	  spectrum	  disorders	  in	  
several	  unrelated	  patients	  with	  NBEA	  gene	  disruptions,	   including	  monoallelic	   gene	  deletions	   [181],	  
SNP	   [182]	   and	   copy	   number	   variations	   [183].	  NBEA	   is	   involved	   in	   post-­‐Golgi	  membrane	   trafficking	  
and	   in	   the	   process	   of	   regulated	   secretion.	   Thereby,	   it	   contributes	   to	   neurotransmission	   at	  
neuromuscular	   junctions	  through	  controlling	  neurotransmitter	  release	  [184,	  185].	   Its	  exact	  function	  
is	   still	   unknown	  but	  NBEA	   is	   discussed	   to	   limit	   PKA	   activity	   spatially	   in	   an	  AKAP-­‐typical	  manner	   as	  
both	   increased	   and	   decreased	   phosphorylation	   of	   PKA	   substrates	   have	   been	   found	   in	   platelets	   of	  
mice	  heterozygous	  for	  NBEA	  [186].	  
As	   discussed	   above,	   WAVE-­‐1	   is	   mainly	   expressed	   in	   the	   brain	   and	   an	   important	   player	   in	   actin	  
organization.	   The	   depletion	   of	   WAVE-­‐1	   in	   knockout	   mice	   causes	   sensorimotor	   retardation	   and	  
reduced	  learning	  and	  memory	  [187,	  188].	  In	  its	  active	  dephosphorylated	  form,	  WAVE-­‐1	  initiates	  actin	  
polymerization	   and	   thus	   facilitates	   neurotransmitter-­‐induced	   neurite	   outgrowth	   and	   neuronal	  
plasticity	   [189].	   Neuronal	   tyrosine-­‐phosphorylated	   adaptors	   for	   the	   phosphoinositide	   3-­‐kinase	  
(NYAP)	   family	   of	   phosphoproteins	   have	   been	   identified	   as	   interaction	   partners	   of	   the	   WAVE-­‐1	  
complex	   in	   developing	   neurons	   [190].	   The	   ternary	   complex	   of	   phosphoinositide	   3-­‐kinase	   (PI3K),	  
NYAPs	  and	  the	  WAVE-­‐1	  complex	  is	  recognized	  as	  another	  example	  of	  spatial	  and	  temporal	  control	  of	  
signaling	  components	  to	  subcellular	  compartments	  in	  close	  vicinity	  of	  PI3K	  for	  regulation	  of	  neuronal	  
morphogenesis	   [191].	   Aberrant	   PI3K	   signaling	   is	   linked	   to	   altered	   developmental	   processes	   of	   the	  
nervous	   system	   and	   to	   neurological	   diseases	   characterized	   by	   cognitive	   and	   behavioral	   deficits	  
including	  intellectual	  disability,	  autism,	  epilepsy	  and	  schizophrenia	  [192].	  	  
	  
Figure	   9:	  AKAPs	   involved	   in	   neuronal	   processes	   such	   as	   increased	   pain	   sensitivity	   (AKAP150)	   and	   neuronal	   development	   (WAVE-­‐1).	  
During	  long-­‐term	  depression	  (LTD),	  the	  redistribution	  of	  AMPA	  receptors	  is	  mediated	  by	  an	  AKAP150-­‐PKA	  complex:	  AKAP150-­‐bound	  PKA	  
induces	  phosphorylation	  of	  A-­‐amino-­‐3-­‐hydroxy-­‐5-­‐methyl-­‐4-­‐isoxazolepropionic	  acid	   receptor	   (AMPA	  R)	  and	   thus	   the	   insertion	  of	  AMPA	  R	  
into	  the	  post-­‐synaptic	  membrane,	  while	  AKAP150-­‐bound	  PP2B	  (calcineurin)	  triggers	  AMPA	  R	  to	  reside	  on	  intracellular	  vesicles.	  PP2B	  also	  
dephosphorylates	  TRPV1,	  while	  PKA	   increases	  TRPV1	  phosphorylation,	   leading	   to	  pain	  sensitivity	   increases	  up	   to	  chronic	  pain	   in	  case	  of	  
continuous	  channel	  activation.	  In	  addition,	  the	  complex	  of	  WAVE-­‐1,	  PKA,	  NYAP	  and	  PI3K	  is	  involved	  in	  neuronal	  cytoskeleton	  remodeling.	  
The	  receptor	  mediating	  Contactin-­‐dependently	  the	  activation	  of	  an	  Fyn-­‐NYAP-­‐PI3K-­‐Rac	  pathway	  is	  currently	  unknown.	  Active	  NYAP,	  after	  
phosphorylation	   by	   Fyn	   tyrosine-­‐protein	   kinase,	   recruits	   and	   activates	   PI3K	   as	   well	   as	   the	   WAVE-­‐1-­‐PKA	   complex.	   Cdk5-­‐dependent	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phosphorylation	   of	   WAVE-­‐1	   inhibiting	   Arp2/3-­‐mediated	   actin	   polymerization	   is	   inhibited	   by	   PKA;	   hence	   PKA	   triggers	   F-­‐actin	   filament	  
elongation	  by	  Arp2/3.	  	  
	  
In	  addition,	  altered	  cAMP	  signaling	  is	  associated	  with	  a	  plethora	  of	  neurodegenerative	  diseases	  such	  
as	   Alzheimer´s,	   Parkinson´s	   and	   Huntington´s	   disease,	   recently	   reviewed	   by	   Poppinga	   et	   al.	   [161].	  
This	  points	  out	  the	  obvious	  physiological	  relevance	  of	  cAMP,	  PKA	  and	  AKAPs	  in	  the	  healthy	  neuronal	  
system	   as	   well	   as	   in	   disease.	   Thus	   targeting	   AKAP-­‐dependent	   protein-­‐protein	   interactions	   in	   the	  
nervous	   system	   with	   specific	   pharmacological	   agents	   might	   be	   an	   option	   for	   the	   treatment	   of	  
neuronal	  disorders.	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Table	  1:	  AKAPs	  and	  their	  relevance	  in	  pathophysiology	  	  















Heart	  failure	  (decreased	  interaction	  
with	  PKA)	  [194];	  
Obesity	  (reduced	  gene	  expression)	  
[96];	  HIV	  replication	  and	  infection	  
[146,	  147]	  
AKAP2	   AKAP2	   Actin	  cytoskeleton,	  
apical	  membrane	  
of	  epithelial	  cells	  
N/A	   Heart	  failure	  (increased	  interaction	  
with	  PKA)	  [194];	  
Kallmann	  syndrome,	  bone	  anomalies	  
(gene	  disruption)	  [195]	  






Cervical,	  breast,	  prostate	  cancer	  
(cancer	  testes	  antigen)	  [137]	  












(Mouse	  KO)	  [84]	  
Polycystic	  kidney	  disease	  
(dysregulation,	  impaired	  Ca2+	  entry,	  
elevated	  cAMP)	  [75];	  
Diabetes,	  metabolic	  syndrome	  [85]	  





cardiac	  remodeling	  	  
(cardiac	  myocyte-­‐
specific	  mouse	  KO)	  
[196]	  
Cardiac	  myocyte	  hypertrophy	  [197];	  
mAKAP	  ablation	  beneficial	  in	  heart	  
disease	  [196]	  
AKAP18α	   AKAP7	   Plasma	  membrane	   Normal	  response	  to	  
adrenergic	  
stimulation	  (KD	  in	  
cardiac	  myocytes)	  
[40]	  
Heart	  failure	  (increased	  interaction	  
with	  PKA)	  [194]	  
AKAP18ɣ,	  δ	   AKAP7	   Cytosol,	   SR,	  
secretory	  vesicles	  
Normal	  response	  to	  
adrenergic	  
stimulation	  (KD	  in	  
cardiac	  myocytes)	  
[40]	  
Ca2+	  reuptake	  into	  the	  sarcoplasmic	  
reticulum	  of	  cardiac	  myocytes	  during	  
diastole	  (AKAP18ɣ	  in	  human,	  AKAP18,	  
δ	  in	  rat)	  [38,	  198]	  
AKAP95	   AKAP8	   Nuclear	  matrix	   viable	  with	  no	  
overt	  phenotype	  
(mouse	  KO)	  [199]	  
N/A	  
AKAP350/AKAP450	   AKAP9	   Centrosomes,	  
Golgi	  (epithelial	  
cells)	  
N/A	   Increased	  breast	  cancer	  risk	  (SNP)	  
[200]	  






in	  sperm	  (mouse	  
KO)	  [201]	  
Heart	  failure	  (decreased	  interaction	  
with	  PKA)	  [194];	  cardiac	  arrhythmias	  
and	  long	  Q-­‐T	  syndrome	  (genetic	  
polymorphism	  Ser1570Lys)	  [202];	  
male	  infertility	  (allelic	  mutations)	  
[201]	  
D-­‐AKAP2	   AKAP10	   Mitochondria,	  
cytosol,	  
endosomes	  
Shortened	  life	  span	  
due	  to	  cardiac	  
arrhythmia	  
(AKAP10ΔRBD	  gene	  
mutation	  in	  mice)	  
[203]	  
Negative	  effect	  on	  longevity	  (SNP)	  
[204];	  increased	  basal	  heart	  rate,	  
reduced	  heart	  rate	  variability	  [203]	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decreased	  (KD	  in	  
metastatic	  human	  
cancer	  cell	  lines)	  
[205]	  
Overexpressed	  in	  tumors,	  oral	  
carcinogenesis	  [206]	  




Various	  solid	  tumors	  (Gene	  
expression	  suppressed,	  
hypermethylation	  of	  the	  promoter,	  
increased	  metastasis)	  [126-­‐131]	  ;	  
acute	  myeloid	  leukemia	  (decreased	  
expression)	  [134]	  






(mouse	  KO)	  [208]	  
Familial	  breast	  cancer	  (genetic	  
polymorphism	  Lys526Gln)	  [111];	  
uterine	  leiomyoma;	  	  
hypertrophic	  cardiomyopathy	  
(increased	  transcript	  levels,	  cardiac	  
fibroblast	  reprogramming	  towards	  
cardiomyoblasts,	  α1-­‐adrenoceptor-­‐
mediated	  cardiac	  hypertrophy)	  [26,	  
48,	  49]	  
	  
Ezrin	  (AKAP78)	   EZR	   Actin	  cytoskeleton	   Enhanced	  HIV-­‐1-­‐
induced	  cell-­‐cell	  
fusion	  assisiting	  
virus	  spreading	  (KD	  
in	  cultured	  T	  
lymphoblasts)	  
[152]	  
HIV	  transmission,	  immune	  response	  
(Increased	  T	  cell	  activation)	  [144]	  







Heart	  failure	  (increased	  interaction	  
with	  PKA)	  [194];	  preserved	  speech	  
variant	  of	  Rett	  syndrome	  (gene	  
deletion)	  [210]	  






in	  mouse	  platelets)	  
[186]	  
Autism	  (gene	  disruption	  or	  partial	  
deletion)	  [181,	  182,	  211]	  













optic	  nerve	  degeneration;	  
multisystem	  neurological	  disease,	  e.g.	  
optic	  atrophy	  (various	  gene	  
mutations)	  [213]	  
SKIP	   SPHKAP	   Cytosol	   N/A	   Heart	  failure	  (increased	  interaction	  
with	  PKA)	  [194]	  






(mouse	  KO)	  [188]	  
N/A	  
Abbr.:	  	  HGNC:	  human	  genome	  nomenclature	  committee;	  KO:	  knockout;	  KD:	  knockdown;	  SNP:	  single	  nucleotide	  
polymorphism.	  N/A,	  not	  available.	  
	  
Recent	  advances	  in	  3D	  structural	  analysis	  of	  AKAPs	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A	   detailed	   understanding	   of	   the	   functioning	   of	   AKAPs	   requires	   insight	   into	   their	   3D	   structures.	   An	  
understanding	  of	  AKAPs	   and	   their	   protein-­‐protein	   interactions	   at	   the	   atomic	   level	   permits	   rational	  
design	  of	  pharmacological	  agents	  for	  selective	  targeting	  of	  individual	  AKAPs	  and	  their	  protein-­‐protein	  
interactions.	  
AKAP-­‐PKA	  interactions	  
AKAP-­‐PKA	   interactions	  are	  mediated	  by	  highly	  conserved	  A-­‐kinase	  binding	  domains	   (AKB)	  of	  AKAPs	  
and	   the	   dimerization	   and	   docking	   (D/D)	   domains	   of	   the	   N-­‐termini	   of	   R	   subunits	   of	   PKA.	   The	   D/D	  
domains	  of	  R	  subunits	  dimerize	  and	  form	  a	  hydrophobic	  groove	  as	  a	  docking	  site	  for	  the	  AKAP.	  D/D	  
domains	  are	  X-­‐type	  four	  helix	  bundle	  structures	  [3,	  4,	  214-­‐218].	  	  
AKBs	   of	   the	  AKAP	   family	   are	   structurally	   conserved	   amphipathic	   α-­‐helices	   of	   14-­‐18	   amino	   acids	   in	  
length	   [219].	   NMR	   and	   X-­‐ray	   crystallographic	   analyses	   of	   AKB-­‐derived	   peptides	   of	   several	   AKAPs	  
confirmed	  the	  α-­‐helical	  structure	  and	  showed	  that	  the	  hydrophobic	  phase	  of	  the	  helix	  docks	  into	  the	  
hydrophobic	  groove	  formed	  by	  the	  D/D	  domain.	  The	  hydrophilic	  phase	  of	  the	  helix	  can	  interact	  with	  
hydrophilic	   amino	   acids	   at	   the	   rim	   of	   the	   D/D	   domain.	   Such	   interactions	   apparently	   increase	   the	  
binding	  affinity	  [53,	  214,	  215,	  220,	  221].	  	  
A	  consensus	  sequence	  of	  polar	  and	  hydrophobic	  amino	  acids	  in	  conserved	  positions	  defines	  an	  AKAP	  
signature	   motif:	   [AVLISE]-­‐X-­‐X-­‐[AVLIF]-­‐[AVLI]-­‐X-­‐X-­‐[AVLI]-­‐[AVLIF]-­‐X-­‐X-­‐[AVLISE]	   (X	   =	   any	   amino	   acid,	  
amino	  acids	   in	   []	   represent	  alternatives	  at	   this	  position)	   [222,	  223].	   This	  AKAP	   signature	  motif	  was	  
used	  to	  screen	  protein	  databases	  for	  new	  AKAPs.	  This	  approach	  identified	  GSK3β	  interaction	  protein	  
(GSKIP)	   as	   an	   AKAP	   [223].	   Recently,	   another	   bioinformatics	   tool	   for	   the	   mapping	   of	   PKA	   binding	  
domains	  and	  the	  prediction	  of	  novel	  AKAPs,	  THAHIT	  (the	  AKAP/amphipathic	  helix	  identification	  tool),	  
was	   introduced	   and	   a	   list	   of	   new	   RIα	   and	   RIIα	   binding	   domains	   for	   existing	   AKAPs	  was	   published	  
suggesting	  that	  various	  AKAPs	  are	  D-­‐AKAPs	  [224].	  This	  new	  tool	  not	  only	  uses	  sequence	  information	  
from	   the	   PKA	   binding	   domains	   of	   the	   known	   AKAPs	   but	   also	   includes	   the	   available	   structural	  
information.	   THAHIT	   identified	   novel	   AKAPs,	   including	   a	   so	   far	   unknown	   AKAP	   of	   330	   kDa	   that	   is	  
expressed	  in	  heart.	  
GSKIP	  is	  so	  far	  the	  only	  AKAP	  with	  a	  nearly	  fully	  resolved	  3D	  structure	  (Protein	  Data	  Bank	  code	  1sgo);	  
of	   its	  139	  amino	  acids	  only	  the	  N-­‐terminal	  32	  amino	  acids	  appeared	  unstructured	  in	  NMR	  analyses.	  
The	   AKB	   resides	   between	   amino	   acids	   28	   and	   52.	   The	   hydrophobic	   phase	   of	   the	   helix	   lies	   on	   the	  
surface	   of	   the	   protein;	   the	   hydrophilic	   phase	   is	   buried	   by	   a	   β-­‐sheet	   that	   follows	   the	   AKB	   in	   the	  
primary	   structure	   (amino	   acids	   49-­‐115).	   The	   β-­‐sheet,	   in	   turn,	   is	   followed	   by	   an	   α-­‐helix	   that	   binds	  
GSK3β	  (amino	  acids	  116-­‐139).	  GSKIP	  facilitates	  the	  phosphorylation	  of	  GSK3β	  at	  Serine	  9	  by	  PKA	  and	  
thereby	  the	  inactivation	  of	  GSK3β	  [223].	  	  
Since	   3D	   structures	   of	   other	   full-­‐length	   AKAPs	   are	   not	   available,	   the	   positions	   of	   AKBs	  within	   the	  
proteins	  are	  unknown.	  However,	  this	   is	  relevant	  as	  AKAP-­‐PKA	  interactions	  are	  apparently	  regulated	  
by	   AKAP-­‐inherent	  mechanisms.	   The	   β-­‐sheet	   covering	   the	   AKB	   of	   GSKIP	  may	   have	   to	   be	   displaced	  
prior	  to	  R	  subunit	  binding	  or	  for	  modulating	  the	  affinity	  of	  the	  interaction	  [223].	  The	  binding	  affinity	  
of	  AKAP18δ	  for	  PKA	  is	  influenced	  by	  its	  N	  terminus;	  a	  N-­‐terminally	  truncated	  version	  lacking	  the	  first	  
123	  amino	  acids	  binds	  RII	  subunits	  of	  PKA	  with	  higher	  affinity	  than	  the	  full-­‐length	  protein:	  KD	  =	  9	  nM	  
for	  AKAP18δ(124-­‐353)	  and	  KD	  =	  31	  nM	  for	  full-­‐length	  AKAP18δ	  [68,	  225].	  	  
A	  crystal	  structure	  of	  the	  central	  part	  of	  the	  353	  amino	  acids	  long	  AKAP18δ	  (amino	  acids	  76–292)	  is	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available	   [226].	   Although	   this	   structure	   is	   lacking	   the	   C-­‐terminal	   AKB	   (amino	   acids	   301-­‐314)	   it	  
revealed	   the	   positions	   of	   positively	   charged	   amino	   acids	   that	   form	   a	   binding	   surface	   for	   the	  
interaction	  with	  negatively	  charged	  membrane	  lipids	  and	  thus	  form	  the	  membrane-­‐targeting	  domain	  
of	  this	  AKAP	  [227].	  The	  positively	  charged	  amino	  acids	  are	  distantly	  located	  in	  the	  primary	  structure	  
but	   concentrate	   in	   the	   tertiary	   structure	   and	   form	   a	   clear	   binding	   surface	   that	   can	   engage	   in	  
electrostatic	   interactions	  with	  membrane	   lipids.	   The	   defined	   binding	   surface	   does	   not	   explain	   the	  
specific	   binding	   of	   AKAP18δ	   to	   AQP2-­‐bearing	   membranes	   (see	   above)	   [225],	   as	   the	   electrostatic	  
interactions	  rather	  point	  to	  non-­‐selective	  binding	  to	  any	  negatively	  charged	  membrane	  and	  to	  a	  yet	  
undefined	   protein-­‐lipid	   or	   protein-­‐protein	   interaction	   conferring	   specificity	   to	   the	   intracellular	  
targeting	  of	  this	  AKAP.	  
Lessons	  from	  AKAP-­‐based	  signalosome	  studies	  
Recent	  electron	  microscopy	  and	  molecular	  modeling	  studies	  [228]	  indicated	  for	  the	  first	  time	  the	  3D	  
arrangement	  of	  an	  AKAP	  together	  with	  PKA	  in	  a	  complex.	  Scott	  and	  colleagues	  found	  that	  AKAP18γ	  
and	  PKA	  type	  II	  are	  in	  a	  pentameric	  configuration	  and	  suggest	  that	  the	  flexible	  linker	  region	  of	  the	  RII	  
subunits	   that	   is	   located	   C-­‐terminally	   from	   the	   D/D	   domain	   confers	   a	   radius	   of	   16	   nm	   to	   the	   C	  
subunits.	  Within	  this	  distance	  the	  C	  subunits	  phosphorylate	  nearby	  substrates	  such	  as	  PDE4D	  bound	  
to	  AKAP18γ.	  Surprisingly,	  the	  authors	  did	  not	  find	  a	  complete	  dissociation	  of	  the	  pentameric	  complex	  
in	  response	  to	  cAMP	  elevation	  in	  HEK293	  cells	  where	  the	  complex	  components	  were	  overexpressed.	  
This	   is	   in	   contrast	   to	   earlier	   findings	   in	   renal	   principal	   cells	   where	   an	   elevation	   of	   cAMP	   leads	   to	  
dissociation	  of	  the	  endogenously	  expressed	  RII	  subunits	  and	  C	  subunits	  from	  AKAP18δ	  [68].	  Possibly,	  
due	   to	   the	  differences	   in	   their	  N	   termini	  AKAP18γ	  and	  AKAP18δ	  behave	  differently	  with	   regard	   to	  
cAMP	  responsiveness.	  
AKAP79	  interacts	  with	  a	  variety	  of	  protein	  binding	  partners,	  including	  calcineurin,	  RII	  subunits	  of	  PKA	  
and	  the	  Ca2+-­‐binding	  protein	  Calmodulin	   (CaM).	  Quantitative	  biochemical	  analyses	  and	  native	  mass	  
spectrometry	  led	  to	  a	  3D	  model	  of	  an	  AKAP79-­‐based	  protein	  complex	  comprising	  these	  proteins.	  The	  
model	   indicates	   dimerization	   of	   AKAP79	   and	   shows	   binding	   of	   two	   AKBs,	   four	   calcineurin	  
heterodimers	   and	   two	   CaMs.	   AKAP79	   concentrates	   these	   proteins	   at	   the	   plasma	   membrane	   and	  
establishes	  a	  local	  signalosome	  that	  can	  respond	  to	  two	  second	  messengers,	  cAMP	  and	  Ca2+	  [229].	  
In	   hippocampal	   neurons,	   AKAP79	   sequesters	   calcineurin	   to	   L-­‐type	   Ca2+	   channels	   and	   couples	   Ca2+	  
influx	   through	   the	   channels	   to	   the	   activation	   of	   calcineurin	   and	   of	   its	   substrate,	   the	   transcription	  
factor	  Nuclear	  factor	  of	  activated	  T-­‐cells	  (NFAT).	  X-­‐ray	  analyses	  revealed	  details	  of	  the	  interaction	  of	  
AKAP79	  with	  calcineurin	  [230].	  A	  sequence,	  IAIIIT,	  of	  AKAP79	  directly	  binds	  calcineurin.	  The	  AKAP79	  
site	  binds	   to	   the	  same	  site	  as	   the	  PxIxIT	  motif	  of	  NFAT.	   In	   line,	  altering	   the	  AKAP79	  binding	  site	   to	  
decrease	  the	  affinity	  leads	  to	  activation	  of	  NFAT;	  vice	  versa,	  increasing	  the	  affinity	  of	  the	  calcineurin-­‐
AKAP79	  interaction	  reduces	  NFAT	  activation.	  Although	  this	  structural	   information	  yields	  insight	  into	  
the	  mechanisms	  underlying	  the	  AKAP79-­‐calcineurin	  interaction	  and	  its	  functional	  role	  with	  regard	  to	  
NFAT	   activation	   it	   is	   unclear	   whether	   the	   3D	   structure	   should	   be	   a	   basis	   for	   a	   drug	   discovery	  
program.	  NFAT	  activation	  in	  cardiac	  myocytes	  occurs	  through	  a	  signalosome	  consisting	  of	  mAKAPβ,	  
calcineurin,	  PKA	  and	  the	  RyR2	  and	  controls	  gene	  expression	  but	  is	  also	  involved	  in	  the	  development	  
of	  cardiac	  hypertrophy.	  Thus	  consequences	  of	  pharmacological	  interference	  are	  difficult	  to	  predict.	  
The	  interaction	  of	  AKAP-­‐Lbc	  and	  RhoA	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AKAP-­‐Lbc	  belongs	  to	  the	  Dbl	  family	  of	  RhoGEFs,	  whose	  RhoGEF	  activity	  is	  conferred	  by	  a	  tandem	  Dbl	  
homology	   (DH)	   and	   pleckstrin	   homology	   (PH)	   domain	   (amino	   acids	   1972-­‐2342)	   [231-­‐233].	   DH	  
domains	  bind	  GTPases	  of	  the	  Rho	  family,	  catalyze	  the	  exchange	  of	  GDP	  for	  GTP	  and	  thereby	  activate	  
the	  GTPases.	  AKAP-­‐Lbc	  selectively	  activates	  RhoA	  but	  not	  other	  members	  of	  the	  Rho	  family	  such	  as	  
Rac	  and	  Cdc42	  [22].	  PH	  domains	  can	  control	  the	  localization	  and/or	  the	  activity	  of	  DH	  domains	  [231].	  
A	  crystal	  structure	  of	  the	  complex	  between	  RhoA-­‐GDP	  and	  the	  AKAP-­‐Lbc-­‐DHPH	  domain	  showed	  that	  
the	   PH	   domain	   is	   connected	   with	   the	   DH	   domain	   by	   a	   helical	   linker	   and	   that	   the	   switch	   I	   and	   II	  
regions	   of	   RhoA	   bind	   to	   two	   distinct	   regions	   of	   the	   DH	   domain.	   The	   binding	   of	   RhoA	   induces	   a	  
conformational	   change	   in	   the	   “GEF	   switch”.	   The	  PH	  domain	  does	  not	   affect	   the	   activity	   of	   the	  DH	  
domain	   [234].	   The	   PH	   domain	   does	   apparently	   not	   interact	   with	   lipids	   explaining	   why	   Onco-­‐Lbc	  
remains	  soluble	  [110].	  	  
The	  affinity	  for	  the	  binding	  of	  RhoA	  to	  the	  AKAP-­‐Lbc-­‐DHPH	  domain	  is	  around	  20	  µM,	  i.e.	  a	  low	  affinity	  
interaction	   that	   can	   potentially	   be	   targeted	   by	   inhibitors	   [234],	   e.g.	   for	   treatment	   of	   cardiac	  
hypertrophy	  and/or	  cancer	  (see	  above).	  	  
Dynamic	  regulation	  of	  AKAP	  signalosomes	  
AKAP	   complexes	   are	  dynamically	   regulated	   at	   several	   levels.	  A	   redistribution	  within	   cells	   has	  been	  
observed	   for	   some	  AKAPs,	  amongst	   them	  two	  actin-­‐associated	  AKAPs	   (Gravin,	  WAVE1).	  Gravin	  can	  
undergo	   trafficking	   from	   the	   cortical	   plasma	   membrane	   to	   the	   cytosol	   in	   response	   to	   stimuli	  
following	  the	  elevation	  of	  intracellular	  calcium,	  involving	  not	  only	  PKA-­‐dependent	  signaling	  but	  also	  
the	  activation	  of	  PKC	  [235].	  WAVE1,	  in	  complex	  with	  RII	  subunits	  of	  PKA	  and	  the	  actin-­‐interacting	  Abl	  
tyrosin	   kinase	   shuttles	   cell-­‐cycle-­‐dependently	   between	   the	   nuclear	   cortex	   and	   cytoplasmic	   foci	   in	  
oocytes	   [236];	   the	   translocation	   is	   essential	   for	   genomic	   and	   cytoskeletal	   dynamics	   during	  
mammalian	   fertilization:	   while	   WAVE1	   is	   distributed	   throughout	   the	   cytoplasm	   of	   metaphase	   II	  
oocytes	  (co-­‐localized	  with	  RII),	  WAVE1	  relocalization	  towards	  the	  developing	  pronuclei	  is	  observable	  
8	  h	  after	  sperm	  entry	  (insemination)	  accompanied	  by	  complete	  RII	  and	  Abl	  reorganization	  inside	  the	  
pronuclei.	   The	   nuclear	  WAVE1	   distribution	   stays	   until	   the	   nuclear	   envelope	   is	   broken	   down	   again	  
during	  mitosis.	  The	  postsynaptic	   localization	  of	  PKA	  upon	  NMDA	  receptor	  activation	  is	  mediated	  by	  
the	  translocation	  of	  AKAP150	  [237].	  Smith	  et	  al.	  demonstrated	  that	  brief	  NMDA	  receptor	  activation	  
leads	   to	   a	   long-­‐lasting	   redistribution	   of	   AKAP79/150	   and	  PKA-­‐RII,	   but	   not	   PP2B,	   from	  postsynaptic	  
membranes	   to	   the	   cytoplasm	   in	   hippocampal	   neurons.	   AKAP79/150	   trafficking	   requires	   PP2B	  
activation	  and	  is	  accompanied	  by	  dephosphorylation	  and	  internalization	  of	  AMPA	  R	  subunit	  GluR1.	  In	  
renal	   principal	   cells,	   the	   AVP-­‐induced	   elevation	   of	   cAMP	   leads	   to	   the	   disassembly	   of	   the	   vesicular	  
AKAP18δ-­‐PKA	   complex:	   not	   only	   dissociate	   the	   catalytic	   subunits	   from	   the	   RII	   subunits	   that	   are	  
bound	   to	   the	   AKAP,	   the	   RII	   subunits	   also	   dissociate	   from	   AKAP18δ;	   and	   AKAP18δ	   translocates	  
together	   with	   AQP2	   from	   intracellular	   vesicles	   to	   the	   plasma	   membrane	   (see	   above;	   [68]).	   The	  
functional	   significance	   of	   the	   observed	   dissociation	   of	   RII	   subunits	   from	   the	   AKAP	   is	   unknown,	  
possibly	   the	   released	   RII	   subunits	   inactivate	   the	   free	   catalytic	   subunits,	   constituting	   a	   negative	  
feedback	  loop.	  Also	  the	  interaction	  of	  AKAP95	  with	  RII	  subunits	  can	  be	  regulated.	  CDK1	  mediates	  the	  
phosphorylation	  of	  T54	  of	  RIIα	  subunits.	  The	  phosphorylated	  RIIα	  binds	  to	  AKAP95.	  The	  AKAP95-­‐PKA	  
complex	  participates	   in	   remodeling	  chromatin	  during	  mitosis.	  Thus	  AKAPs	  are	  not	   solely	   stationary	  
anchors	  in	  cells	  but	  can	  also	  serve	  as	  dynamic	  signaling	  components.	  
Current	  strategies	  to	  interfere	  with	  AKAP-­‐dependent	  protein-­‐protein-­‐interactions	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Pharmacological	   interference	   is	  an	  approach	  for	  elucidating	   functions	  of	  AKAPs	  and	  their	   individual	  
protein-­‐protein	   interactions.	   The	   ongoing	   efforts	   focus	   on	   targeting	   AKAP-­‐PKA	   interactions	   with	  
peptides,	   peptidomimetics	   and	   small	   molecules.	   Other	   AKAP-­‐dependent	   interactions	   are	   targeted	  
with	  peptides	  derived	  from	  the	  binding	  domain	  of	  either	  the	  AKAP	  or	  its	  interacting	  partner.	  	  
Disruptor	  peptides	  
The	  first	  AKAP-­‐PKA	  disruptor	  peptide,	  Ht31,	  was	  derived	  from	  the	  AKB	  of	  AKAP-­‐Lbc	  and	  characterized	  
almost	   three	  decades	  ago	   [219].	  As	   synthetic	  peptide	  or	  expressed	   from	  vectors,	  Ht31	  was	   rapidly	  
established	  as	  a	  valuable	  tool	  to	  study	  functional	  implication	  of	  anchored	  PKA	  signaling	  in	  a	  variety	  of	  
cell	  systems	  and	  animal	  models.	  Ht31	  and	  other	  AKAP-­‐derived	  peptides	  bind	  to	  the	  D/D	  domain	  of	  
PKA	  and	  compete	  with	  AKAPs	  for	  PKA	  binding.	  However,	  they	  do	  not	  distinguish	  between	  RI	  and	  RII	  
PKA	   subunits	   and,	   therefore,	   cannot	   discriminate	   between	   RI-­‐	   and	   RII-­‐mediated	   processes.	  
Bioinformatics	   approaches	   and	   peptide-­‐array	   based	   optimization	   processes	   introduced	   a	   new	  
generation	  of	  PKA	  anchoring	  disruptor	  peptides	  [25].	  AKAP-­‐in	  silico	   (AKAP-­‐IS)	  and	  AKAP18δ-­‐derived	  
peptides	  with	  nanomolar	  affinities	  for	  both	  R	  subunits	  were	  developed	  [238].	  RI-­‐	  and	  RII-­‐preferring	  
and	  RI-­‐	  and	  RII-­‐specific	  peptides	  are	  available	  now,	  e.g.	   the	  RI	  anchoring	  disruptor,	  RIAD	   [239]	  and	  
SuperAKAP-­‐IS	  for	  RII	  [214];	  the	  dual-­‐specific	  D-­‐AKAP2	  was	  used	  as	  template	  for	  the	  generation	  of	  RI-­‐	  
and	  RII-­‐preferring	  peptides	  [240].	  All	  peptides	  are	  available	  as	  membrane-­‐permeant	  versions	  for	  cell-­‐
based	  studies.	  For	  membrane	  permeation	  tags	  such	  stearate,	  myristoylic	  acid	  or	  TAT	  sequences	  have	  
been	  used	  [25].	  
As	  the	  mode	  of	  interaction	  of	  AKAPs	  with	  PKA	  is	  conserved	  (see	  above),	  all	  of	  the	  disruptor	  peptides	  
globally	   uncouple	   PKA	   from	   AKAPs,	   either	   type	   I	   or	   type	   II	   but	   in	   most	   cases	   both	   types	   of	   PKA.	  
Recently,	  Gold	  et	  al.	  employed	  a	  phage	  display	  method	  to	  derive	  peptides	  from	  the	  D/D	  domain	  of	  
RII	  subunits	  and	  engineered	  them	  in	  a	  way	  that	  they	  became	  binders	  for	  a	  limited	  number	  of	  AKAPs.	  
The	   peptides	   RSelectAKAP2	   and	   RSelectAKAP18	   preferentially	   bound	  AKAP2	   and	   AKAP18,	   respectively.	  
These	  peptides	  represent	  new	  molecular	  tools	  that	  allow	  studying	  functions	  of	  a	  limited	  set	  of	  AKAP-­‐
PKA	  interactions	  [241].	  
Peptides	  were	  also	  used	  to	  target	  protein-­‐protein	  interactions	  of	  AKAPs	  other	  than	  those	  with	  PKA.	  
Some	   studies	   have	   been	   performed	   with	   peptides	   perturbing	   disease-­‐related	   AKAP-­‐dependent	  
protein-­‐protein	   interactions	   [e.g.	   the	   AKAP18δ-­‐PLN	   binding	   [38]	   and	   AKAP18α-­‐L-­‐type	   Ca2+	   channel	  
interactions	  [242]].	  	  
A	   drawback	   of	   peptides	   is	   their	   generally	   short	   half-­‐life,	   their	   low	  membrane-­‐permeation	   and	   low	  
oral	  bioavailability,	  which	  limits	  their	  use	  for	  cell	  and	  animal	  studies.	  In	  addition,	  they	  are	  considered	  
difficult	  for	  the	  development	  towards	  drugs,	  although	  several	  peptide-­‐based	  drugs	  have	  reached	  the	  
market	  [243].	  	  
Small	  molecules	  
Small	   molecules	   are	   considered	   as	   an	   alternative	   to	   peptides.	   Their	   stability	   and	   ability	   to	   cross	  
biological	  membranes	  allow	  their	  use	  in	  cell	  and	  animal	  studies.	  They	  have	  become	  powerful	  tools	  in	  
studying	   functions	   of	   protein-­‐protein	   interactions.	   High-­‐throughput	   screening	   of	   small	   molecule	  
libraries	   facilitates	   the	   discovery	   of	   novel	   compounds	   targeting	   the	   protein	   or	   protein-­‐protein	  
interaction	   of	   interest.	   Identified	   hits	   can	   be	   optimized	   with	   regard	   to	   specificity	   and	   affinity	   by	  
medicinal	  chemistry	  approaches	  [244,	  245].	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The	   first	   small	  molecule	   targeting	   an	   AKAP-­‐dependent	   protein-­‐protein	   interaction	   is	   FMP-­‐API-­‐1.	   It	  
was	  identified	  in	  a	  high-­‐throughput	  screen	  of	  20,000	  druggable	  substances.	  FMP-­‐API-­‐1	  allosterically	  
binds	  RII	  subunits	  and	  thereby	  blocks	  AKAP-­‐PKA	  interactions	  [36,	  246].	   In	  addition,	  PKA	  is	  activated	  
upon	  FMP-­‐API-­‐1	  binding.	  Both	  in	  rat	  neonatal	  cardiac	  myocytes	  and	  ex	  vivo	   in	   intact	  hearts	  the	  net	  
effect	  of	  FMP-­‐API-­‐1	  is	  an	  increase	  in	  cardiac	  contractility.	  	  
The	  membrane-­‐associated	   G	   protein-­‐coupled	   estrogen	   receptor	   1	   (GPER;	   initially	   called	   GPR30)	   is	  
structurally	   unrelated	   to	   nuclear	   ERα	   or	   ERβ.	   In	   hypertension	   and	   ischemia-­‐reperfusion	   models	  
activation	  of	  GPER	  is	  protective	  as	  it	  relaxes	  arteries.	  Inhibition	  of	  AKAP-­‐PKA	  interactions	  with	  FMP-­‐
API-­‐1	   attenuated	   the	   effect	   of	   GPER	   activation	   on	   coronary	   artery	   relaxation	   by	   a	   mechanism	  
involving	  activation	  of	  myosin	  light	  chain	  phosphatase	  and	  inhibition	  of	  a	  RhoA	  pathway	  [247].	  
Peptidomimetics	  
Peptidomimetics	   are	   designed	   to	   combine	   advantages	   of	   peptides,	   i.e.	   the	   specificity	   and	   target	  
selectivity,	  with	  those	  of	  small	  molecules,	  i.e.	  increased	  membrane	  permeation	  and	  stability.	  The	  first	  
peptidomimetic	   for	   inhibition	  of	   an	  AKAP-­‐dependent	  protein-­‐protein	   interaction	  was	  based	  on	   the	  
peptide	  RIAD,	  which	  selectively	  inhibits	  the	  interaction	  of	  RI	  subunits	  of	  PKA	  with	  AKAPs.	  The	  peptide	  
was	   modified	   by	   inclusion	   of	   non-­‐natural	   amino	   acids	   to	   improve	   stability	   [248].	   A	   membrane-­‐
permeant	   version	   reduced	   cAMP	   levels	   in	   HIV-­‐infected	   cultured	   T	   cells.	   In	   a	   mouse	   model,	  
humanized	  NOD/SCID/IL2γnull	  (NSG)	  mice	  infected	  with	  HIV-­‐1	  the	  molecule	  limited	  HIV-­‐1	  replication	  
and	  stabilized	  CD4	  cell	  levels	  by	  interference	  with	  a	  cAMP/PKA	  type	  I	  pathway	  [153].	  
On	   the	   basis	   of	   the	   peptide	   AKAP18δ-­‐L314E,	  which	   binds	   RII	   subunits	  with	   subnanomolar	   affinity,	  
polypyridines	  were	  developed	  as	  helix	  mimetics	   [53,	   220].	   The	   terpyridin-­‐based	   compounds	  mimic	  
the	  hydrophobic	  phase	  of	   the	  peptidic	  α-­‐helix	  by	  projecting	  amino	  acid-­‐derived	   side	   chains	   from	  a	  
hydrophobic	   rod-­‐like	   axis	   [220].	   The	   rod-­‐like	   axis	   is	   composed	   of	   pyridine,	   cyclopentyl	   and	   benzyl	  
rings	   and	   interacts	   with	   the	   bottom	   of	   the	   D/D	   domain	   pocket;	   carboxyl	   groups	   engage	   in	  
interactions	  with	  hydrophilic	  residues	  at	  the	  rim	  of	  the	  D/D	  domain	  pocket	  and	  increase	  the	  binding	  
affinity.	   KD	   values	   for	   the	   interaction	   with	   the	   D/D	   domain	   of	   RIIα	   range	   from	   30	   –	   148	   µM;	   The	  
terpyridines	  inhibit	  the	  interaction	  of	  RIIα	  with	  AKAP18	  with	  IC50	  values	  between	  38	  µM	  and	  138	  µM	  
[220].	  The	  newly	  synthesized	  terpyridine	  scaffolds	  represent	  the	  first	  nonpeptidic,	  biologically	  active	  
compounds	  which	   interfere	  with	   AKAP-­‐PKA	   interactions	   in	   vitro	   as	   well	   as	   in	   vivo	   in	   HEK293	   cells	  
[220].	  Although	  the	  KD	  and	  IC50	  values	  of	  the	  terpyridines	  are	  high	  the	  new	  molecules	  exemplify	  the	  
design	   of	   nonpeptide	   helix	   mimetics	   and	   pave	   the	   way	   to	   novel	   high	   affinity	   compounds	   for	  
disruption	  of	  AKAP-­‐PKA	  interactions.	  
Tab.	  2	  summarizes	  current	  approaches	  yielding	  peptides	  disruption	  AKAP-­‐dependent	  PPIs.	  Of	  note,	  
none	  of	  the	  disruptors	  reached	  the	  phase	  of	  clinical	  trial	  so	  far.	  
	  
Table	  2:	  Current	  inhibitors	  of	  AKAP-­‐protein	  interactions	  and	  their	  physiological	  consequences	  
Type	   Name	   Target	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Peptide	   Ht-­‐31	   AKAP-­‐PKA	  
interaction	  	  
Stimulation	  of	  oocyte	  maturation;	  
Increased	  β-­‐AR-­‐stimulated	  
contractility;	  
Reduced	  AMPA/kainite	  channel	  
currents;	  
Reduced	  antigen	  presentation,	  
inhibition	  of	  TNFα	  and	  IL-­‐10	  
production	  
Mouse	  oocytes	  [193];	  




CD4+	  T	  cells	  [154]	  
	   S-­‐Ht31	   AKAP-­‐PKA	  
interaction	  
Inhibition	  of	  vasopressin-­‐stimulated	  
AQP-­‐2	  translocation;	  
	  
Inhibition	  of	  sperm	  motility	  	  
Renal	  inner	  medullary	  
collecting	  duct	  (IMCD)	  
cells	  [34];	  
Bovine	  caudal	  epididymal	  
sperm	  [31]	  
	   TAT-­‐AKAD	   AKAP-­‐PKA	  
interaction	  
Reduced	  contractility;	  Negative	  effect	  
on	  chronotropy,	  ionotropy	  and	  
lusitropy	  	  
Cardiac	  myocytes	  [250]	  
	   AKAP15-­‐LZ	   AKAP18α-­‐L-­‐type	  
Ca2+	  channel	  
interaction	  
Inhibition	  of	  voltage-­‐dependent	  L-­‐
type	  Ca2+	  channel	  potentiation;	  
Inhibition	  of	  β-­‐adrenoceptor-­‐induced	  
L-­‐type	  Ca2+	  currents	  
Mouse	  skeletal	  muscle	  
cells	  (MM14,	  DZ1A)	  [242];	  
Mouse	  skeletal	  mouse	  
[251]	  
	   AKAP18δ-­‐wt	   AKAP-­‐PKA	  
interaction	  
Reduced	  β-­‐adrenoceptor-­‐induced	  L-­‐
type	  Ca2+	  currents	  






Reduced	  andrenoceptor-­‐induced	  Ca2+	  
reuptake	  into	  the	  SR	  
Rat	  neonatal	  and	  adult	  
cardiac	  myocytes	  [53]	  
	   RIAD-­‐Arg11	   AKAP-­‐PKA	  RI	  
interaction	  
Uncoupling	  of	  cAMP-­‐mediated	  
inhibition	  of	  T	  cell	  function;	  
Reduced	  ACTH-­‐stimulated	  
progesterone	  production	  
T	  cells	  [239];	  
	  
Mouse	  Y1	  adrenocortical	  
cells	  [239]	  
	   AKAP-­‐IS	   AKAP-­‐PKA	  
interaction	  	  
Attenuation	  of	  AMPA	  receptor	  
subunit	  GluR1	  currents;	  
Reduced	  antigen	  presentation	  
HEK293	  cells	  [238];	  
CD4+	  T	  cells,	  KG-­‐1	  
dendritic	  progenitor	  cells	  
[154,	  156]	  
	   TAT-­‐AKAP-­‐IS	   AKAP-­‐PKA	  
interaction	  
Inhibition	  of	  glucagon-­‐induced	  insulin	  
secretion	  potentiation	  

















Colocalization	  with	  AKAP18δ	  and	  
MAP2	  
In	  vitro;	  in	  vivo	  in	  HEK293	  
cells	  [241]	  
	   peptides	  
derived	  
from	  the	  
AKAP-­‐PKA	   RI	  
(PV-­‐38)	   or	  
AKAP-­‐PKA	   RII	  
Colocalization	  with	  R	  subunits	   In	  vitro;	  in	  vivo	  in	  
10T(1/2)	  cells	  [240]	  














Not	  determined	  	   In	  vitro	  [248]	  
	   RIAD-­‐P3	   AKAP-­‐PKA	  RI	  
interaction	  




Limited	  HIV-­‐1	  replication,	  stabilized	  




(PBMCs)	  [153];	  	  
Humanized	  
NOD/SCID/IL2γnull	  (NSG)	  
mice	  infected	  with	  HIV	  
[153]	  







Intracellular	  access	  of	  the	  peptides,	  
decreased	  PKA	  substrate	  
phosphorylation,	  inhibition	  of	  
cytosolic	  PKA	  activity	  
In	  vitro;	  in	  vivo	  in	  human	  
cell	  lines	  (HeLa,	  MDA-­‐MB-­‐
231,	  PC-­‐3)	  [253]	  




AKAP-­‐PKA	   RI	  
interaction	  
Cell	  permeability	  and	  RI	  selectivity	  
proven,	  AKAP-­‐anchored	  signaling	  
disrupted	  
In	  vitro;	  in	  vivo	  in	  human	  




Terpyridines	   AKAP-­‐PKA	  
interaction	  
Prevents	  PGE1-­‐mediated,	  PKA-­‐
dependent	  negative	  feedback	  
inhibiting	  AC	  	  
In	  vitro;	  in	  vivo	  in	  HEK293	  
cells	  [220]	  




Increase	  in	  cardiac	  contractility;	  
	  
Inhibition	  of	  G	  protein	  coupled	  
estrogen	  receptor	  1	  (GPER)-­‐mediated	  
coronary	  artery	  vasodilation	  
Rat	  hearts;	  rat	  neonatal	  
cardiac	  myocytes	  [36];	  
Cultured	  coronary	  artery	  
smooth	  muscle	  cells	  
(SMCs)	  [255]	  
	  
Summary,	  conclusions	  and	  outlook	  
Due	   to	   non-­‐causal	   and	   thus	   ineffective	   treatment,	   the	   medical	   need	   is	   huge	   in	   many	   diseases,	  
including	  cancer	  and	  cardiovascular	  diseases.	  Heart	  failure	  alone	  affects	  26	  million	  people	  worldwide	  
[256]	   and	   imposes	   costs	   for	   health	   care	   and	   lost	   productivity	   of	   an	   estimated	   108	   billion	  USD	   p.a	  
[257].	   In	   2013,	   382	   million	   people	   worldwide	   suffered	   of	   diabetes	   and	   an	   increase	   of	   55	   %	   is	  
estimated	  for	  the	  next	  20	  years	  [258].	  These	  numbers	  stress	  the	  urgency	  for	  new	  therapeutic	  options	  
in	  diseases	  affecting	  large	  parts	  of	  the	  populations	  of	  mainly	  Western	  countries.	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Recent	   progress	   increases	   the	   understanding	   of	   the	   molecular	   mechanisms	   underlying	   the	  
functioning	  of	  AKAPs	  and	  their	  protein-­‐protein	  interactions.	  The	  discovery	  of	  new	  AKAPs,	  elucidation	  
of	  the	  signaling	  processes	  they	  coordinate	  and	  of	  their	  physiological	  relevance	  and	  the	  detection	  of	  
molecular	  aberrations	  related	  to	  AKAPs	  in	  diseases	  hint	  to	  new	  therapeutic	  concepts.	  	  
Due	  to	  their	  multiple	  protein-­‐protein	  interactions	  individual	  AKAPs	  have	  various	  functions.	  As	  in	  the	  
case	  of	  AKAP-­‐Lbc’s	  role	  in	  the	  development	  of	  cardiac	  hypertrophy	  these	  functions	  can	  be	  opposing,	  
e.g.	  promote	  cardiac	  hypertrophy	  or	  be	  protective	  against	  it.	  This	  indicates	  first	  of	  all	  that	  therapeutic	  
interventions	  at	  AKAPs	   require	  a	  detailed	  understanding	  of	   the	  AKAP	  of	   interest	  and	  secondly	   that	  
strategies	   aiming	   at	   the	   elimination	   of	   a	   particular	   AKAP,	   e.g.	   by	   knockdown,	   need	   sceptical	  
consideration	  beforehand,	  as	  loss	  of	  an	  AKAP	  causes	  loss	  of	  all	  of	  its	  functions.	  On	  the	  other	  hand,	  in	  
conditions	   when	   an	   AKAP	   is	   downregulated	   such	   as	   the	   tumor	   suppressor	   gravin	   in	   solid	   tumors,	  
measures	   to	   reconstitute	   its	   expression	   may	   be	   appropriate.	   Such	   strategies	   may	   include	   in	   vitro	  
transcribed	   (IVT)	  mRNA,	  an	  approach	   that	  has	   reached	  clinical	  phase	   III	   trials	   in	   several	   indications	  
including	  breast	  cancer	  [259].	  	  
The	  multiple	  protein-­‐protein	  interactions	  of	  AKAPs	  each	  fulfilling	  different	  functions	  predestine	  them	  
as	   targets	   for	   pharmacological	   interference.	   Generally,	   changes	   in	   the	   specificity	   and	   affinity	   of	  
protein-­‐protein	  interactions	  lead	  to	  malfunctions	  in	  cells	  and	  eventually	  to	  disease,	  making	  protein-­‐
protein	   interactions	   important	  drug	   targets	   for	   the	  next	  generation	  of	   therapies.	   Interference	  with	  
intracellular	  protein-­‐protein	  interaction	  is	  still	  a	  novel	  pharmacological	  concept,	  but	  proof-­‐of-­‐concept	  
has	  been	  reached	  as	  first	  drugs	  have	  been	  approved	  (e.g.	  Tirobifan	  as	  cardiovascular	  drug,	  Maraviroc	  
as	   anti-­‐HIV	   drug)	   [260].	   Tirobifan	   targets	   the	   glycoprotein	   IIb/IIIa	   complex	   on	   platelets	   reducing	  
thrombotic	  cardiac	  events	  e.g.	  myocardial	  infarction	  while	  Maraviroc	  inhibits	  the	  interaction	  of	  HIV-­‐1	  
gp120	  with	  the	  chemokine	  coreceptor	  CCR5,	  a	  key	  step	  of	  HIV-­‐1	  entry	  into	  host	  cells.	  Peptide-­‐based	  
therapy	   is	   of	   high	   relevance	   also	   in	   other	   diseases,	   best	   exemplified	   by	   diabetes	   where	   insulin	  
analogues	  are	  first	  line	  drugs	  for	  treatment,	  recently	  reviewed	  in	  [261].	  
In	  the	  case	  of	  AKAPs,	  interference	  with	  the	  6	  fold	  increased	  interactions	  of	  SPHKAP	  and	  AKAP2,	  the	  
2.4	  fold	  increase	  of	  AKAP18	  and	  the	  12	  fold	  increase	  of	  MAP2	  with	  PKA	  in	  failing	  hearts	  [51]	  makes	  
these	   interactions	   interesting	  targets.	  However,	  AKAP-­‐PKA	   interactions	  are	  highly	  conserved	  and	  at	  
present	  there	  are	  no	  agents	  available	  to	  selectively	  interfere	  with	  the	  interaction	  of	  a	  particular	  AKAP	  
with	  PKA.	  Although	  attempts	  to	  develop	  peptides	  for	  inhibition	  of	  defined	  AKAP-­‐PKA	  interactions	  are	  
ongoing	   and	   some	  degree	  of	   specificity	   has	  been	   reached,	   i.e.	   peptides	   that	   discriminate	  between	  
PKA	  types	  I	  and	  II	  (e.g.	  RIAD)	  and	  peptides	  that	  preferentially	  inhibit	  interactions	  of	  PKA	  with	  AKAP18	  
[241],	   it	   appears	  difficult	   to	   selectively	   target	  defined	  AKAP-­‐PKA	   interactions	  due	   to	   the	   conserved	  
mechanism	   underlying	   these	   interactions.	   This	   conservation	   also	   hampers	   the	   development	   of	  
peptidomimetics	   and	   small	   molecules	   for	   inhibition	   of	   specific	   AKAP-­‐PKA	   interactions.	   The	   first	  
peptidomimetics	  [6,	  153,	  220]	  and	  a	  first	  small	  molecule,	  FMP-­‐API-­‐1,	  for	  the	  non-­‐selective	  disruption	  
of	  AKAP-­‐PKA	   interactions	  are	  available	   [36,	  247].	  There	  are	  hints	   that	  allosteric	  sites	  such	  as	  the	  RI	  
Specifier	  Region	  (RISR)	  in	  D-­‐AKAPs	  [6]	  and	  a	  region	  C-­‐terminally	  from	  the	  D/D	  domain	  of	  RII	  [36]	  are	  
involved	  in	  AKAP-­‐PKA	  interactions.	  Targeting	  such	  allosteric	  sites	  pharmacologically	  may	  reduce	  the	  
affinity	  of	  the	  binding	  or	  even	  inhibit	  the	  interactions,	  as	  the	  sequences	  of	  e.g.	  RISRs	  are	  not	  highly	  
conserved.	  	  
There	  are	  specific	  AKAP-­‐dependent	  protein-­‐protein	  interactions	  that	  appear	  relevant	  for	  disease	  such	  
as	   the	   AKAP-­‐Lbc-­‐RhoA	   interaction	   seems	   relevant	   in	   cardiac	   hypertrophy	   and	   cancer.	   To	   validate	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specific	  disease-­‐relevant	  protein-­‐protein	   interactions	  of	  AKAPs	  as	  drug	  targets,	   the	  development	  of	  
small	  molecules	  for	  their	   inhibition	   is	  desirable.	  They	  are	  stable	  and	  membrane-­‐permeant	  and	  thus	  
suitable	  for	  validation	  procedures	  from	  cultured	  cells	  to	  clinical	  trials.	  Small	  molecules	  for	  targeting	  
AKAP-­‐dependent	   protein-­‐protein	   interactions	   may	   be	   sought	   by	   high-­‐throughput	   screening	   of	  
libraries,	  a	  procedure	  by	  which	  FMP-­‐API-­‐1	  was	  identified,	  or	  by	  rational	  ligand	  design.	  Rational	  design	  
depends	   on	   high-­‐resolution	   structural	   information	   on	   the	   interaction	   of	   interest.	   As	   more	   3D	  
structures	  of	  AKAP-­‐dependent	  protein-­‐protein	  interactions	  become	  available	  (e.g.[230,	  234])	  this	  is	  a	  
likely	   strategy	   to	   be	   followed	   in	   the	   future.	   However,	   the	   prerequisite	   to	   make	   this	   a	   successful	  
strategy	  is	  the	  development	  of	  novel	  approaches	  to	  obtain	  high-­‐resolution	  structures	  of	  AKAPs	  that	  
appear	  largely	  unfolded	  if	  generated	  recombinantly.	  	  
The	   examples	   chosen	   here	   to	   illustrate	   the	   involvement	   of	   AKAPs	   in	   disease	   are	   by	   far	   not	  
exhaustive.	  AKAPs	  play	  roles	  in	  many	  more	  cellular	  processes	  whose	  dysregulation	  leads	  to	  disease.	  
They	   are	   involved	   in	   complex	  mechanisms	   such	   as	  memory	   formation	   and	   blood	   pressure	   control	  
[161,	  262,	  263]	  and	   tether	  different	  protein	  assemblies	   to	  various	  subcellular	  compartments	   [264].	  
Thus	  AKAPs	  are	  a	  rich	  source	  to	  be	  considered	  as	  pharmacological	  targets.	  The	  development	  of	  drug	  
candidates	  targeting	  AKAPs	  and	  their	  testing	  in	  clinical	  trials	  remains	  a	  task	  and	  a	  goal	  for	  the	  future.	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List	  of	  abbreviations	  
AC:	  adenylyl	  cyclase	  
AKAP:	  A-­‐kinase	  anchoring	  protein	  
AKAP-­‐IS:	  AKAP-­‐in	  silico	  
AKAP-­‐Lbc:	  AKAP-­‐Lymphoid	  blast	  crisis	  
AKB:A-­‐kinase	  binding	  domains	  
AQP2:	  Aquaporin-­‐2	  
ASM:	  airway	  smooth	  muscle	  
ATP:	  adenosine	  triphosphate	  
AVP:	  arginine	  vasopressin	  
BAD:	  Bcl-­‐2	  antagonist	  of	  cell	  death	  
BCAM/Lu:	  basal	  cell	  adhesion	  molecule/	  Lutheran	  	  
C:	  catalytic	  
cAMP:	  cyclic	  AMP	  
CD4:	  cluster	  of	  differentiation	  4	  
COPD:	  chronic	  obstructive	  pulmonary	  disease	  
Crk:	  C-­‐terminal	  Src	  	  
Csk:	  C-­‐terminal	  Src	  kinase	  
D/D:	  dimerization	  and	  docking	  
D-­‐AKAP:	  dual-­‐specific	  AKAP	  
DH:	  Dbl-­‐homologous	  
Epac:	  exchange	  proteins	  activated	  by	  phosphatases	  
ERK:	  extracellular	  signalling	  related	  kinase	  
FAK:	  Focal	  adhesion	  kinase	  
FMP-­‐API-­‐1:	  small	  molecule	  identified	  by	  high-­‐throughput	  screen	  by	  Christian	  et	  al.	  [36]	  
GDP:	  guanosine	  diphosphate	  
GEF:	  guanine	  nucleotide	  exchange	  factor	  
GK:	  Glucokinase	  
GLP-­‐1:	  glucagon-­‐like	  peptide	  1	  
GPCR:	  G-­‐protein	  coupled	  receptor	  
GPER:	  G	  protein-­‐coupled	  estrogen	  receptor	  1	  
Gs:	  stimulatory	  G	  protein	  
GSK3β:	  Glycogen	  synthase	  kinase	  3β	  
GSKIP:	  glycogen	  synthase	  kinase	  3β	  (GSK3β)	  interaction	  protein	  
GTP:	  guanosine	  triphosphate	  
HEK:	  human	  embryonic	  kindey	  
HIV:	  human	  immunodeficiency	  virus	  
Ht31:	  peptide	  derived	  from	  RIIBD	  of	  AKAP-­‐Lbc	  
IC50:	  mean	  inhibitory	  concentration	  
IL-­‐8:	  Interleukin	  8	  
KO:	  knockout	  
KSR:	  kinase	  suppressor	  of	  Raf	  
LPL:	  lipoprotein	  lipase	  
mAKAP:	  muscle-­‐selective	  AKAP	  
MAP2D:	  microtubule-­‐associated	  protein	  2D	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MAPK:	  mitogen	  activated	  protein	  kinase	  
MEK:	  mitogen	  activated	  protein	  kinase	  kinase	  (MAPKK)	  
mRNA:	  messenger	  RNA	  
MyBP:	  myosin-­‐binding	  protein	  
NDI:	  nephrogenic	  diabetes	  insipidus	  	  
NFAT:	  nuclear	  factor	  activated	  in	  T-­‐cells	  
NMR:	  nuclear	  magnetic	  resonance	  
OPA1:	  optic	  artrophy	  1	  
PDE:	  phosphodiesterase	  
PGE2:	  prostaglandin	  E2	  
PH:	  pleckstrin	  homology	  
PKA:	  (cAMP-­‐dependent)	  protein	  kinase	  A	  
PKC:	  protein	  kinase	  C	  
PKD:	  Polycystic	  kidney	  disease	  
PKNα:	  protein	  kinase	  Nα	  	  
PLN:	  phospholamban	  
PP1:	  protein	  phosphatase	  1	  
PP2:	  protein	  phosphatase	  2,	  synonym	  for	  calcineurin	  
R:	  regulatory	  
Raf:	  Rat	  fibrosarcoma	  
Ras:	  Rat	  sarcoma	  
RIAD:	  unnatural	  RI	  anchoring	  disruptor	  
RIIBD:	  RII	  binding	  domain	  
RyR2:	  type	  2	  ryanodine	  receptor	  
SERCA2:	  sarcoplasmic	  endoplasmic	  reticulum	  Ca2+	  ATPase	  2	  
shRNA:	  short	  hairpin	  RNA	  
SIADH:	  syndrome	  of	  inappropriate	  antidiuretic	  hormone	  secretion	  	  
SR:	  sarcoplasmic	  reticulum	  
Src:	  Sarcoma	  
SSeCKS:	  Src	  suppressed	  	  
SSeCKs:	  Src-­‐suppressed	  C	  kinase	  substrate	  
TAC:	  Thoracic	  aortic	  constriction	  
TCR:	  T	  cell	  receptor	  
TnI:	  Troponin	  I	  
TRPV1:	  Transient	  Receptor	  Potential	  Vanilloid	  1	  
V2R:	  vasopressin	  V2	  receptor	  
WAVE-­‐1:	  WASP-­‐family	  verprolin	  homologous	  protein	  1	  
Yotiao:	  synonym	  for	  AKAP9	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